December 2008

King exercises option to license fourth opioid product from Acura

December 29, 2008

In connection with the exercise of its option, King paid Acura an option exercise fee of $3.0 million.

Eli Lilly licensing agreement with BioMS Medical

December 29, 2008

Lilly signed a $497 million licensing and development agreement for BioMS’s dirucotide, potentially the first treatment for advanced forms of multiple sclerosis to come to market.

Novartis licenses vaccine candidates from AlphaVax

December 29, 2008

Novartis will pay $20 million upfront. Novartis also acquired first negotiation rights to a respiratory vaccine that is still in animal testing, as well as an option on 4 million AlphaVax shares, to be exercised end of the second stage of clinical tests.

VIA licenses cardiovascular drug candidates from Roche

December 23, 2008

VIA will assume control of all development and commercialization of the compounds, and will own exclusive worldwide rights for all potential indications. The agreements provide for milestone payments for development and royalties upon commercialization.

GlaxoSmithKline and Archemix form strategic alliance to develop aptamers to treat inflammatory diseases

December 23, 2008

Archemix will receive $27.5 million in upfront payments from GSK, including a $6.5 million equity investment by GSK in the company. Archemix could also be eligible to receive up to $200 million in development, regulatory and sales milestone payments for each of the seven aptamer therapeutics which may be discovered and developed as part of the alliance. Archemix would also receive tiered royalties up to lower double digits on worldwide sales of products that may result from the alliance.

AstraZeneca links up with Biocompatibles for GLP-1 Drug

December 23, 2008

Deal could be worth up to Euro 327 million.

Sanofi-Aventis and Novozymes announce development and commercialization collaboration for innovative antibiotic

December 22, 2008

Sanofi-Aventis has been granted an exclusive worldwide license for the development, registration and commercialization of the drug. The two companies will jointly work to develop and implement commercial-scale manufacturing of the Plectasin NZ2114 drug substance, with the goal of introducing a recombinant process building on Novozymes' proprietary expression technology.

Sangamo in license agreement with Pfizer for zinc finger nucleases for protein production

December 22, 2008

Sangamo will receive an upfront payment of $3.0 million from Pfizer for a fully paid license.

Galapagos and GlaxoSmithKline expand osteoarthritis alliance

December 22, 2008

For this expansion, Galapagos receives a payment from GSK of EUR 2 million cash. This payment is in addition to the existing alliance terms, making the total alliance now worth up to EUR 188 million. Including today's payment, Galapagos has received a total of EUR 17.9 million in payments from GSK under this alliance.

ArQule and Daiichi Sankyo signed a license, co-development and co-commercialization agreement to co-develop ARQ 197

December 19, 2008

The definitive agreement supersedes the binding letter of intent announced on November 10, 2008 covering the same subject matter. Consummation of the collaboration, includes receipt of a $60 million cash up-front licensing payment from Daiichi Sankyo.

Novocell in non-exclusive drug discovery collaboration with Pfizer

December 19, 2008

Novocell will receive an upfront payment with additional amounts payable upon the achievement of certain technical milestones, as well as research funding. In addition, Novocell will receive payments relating to the sale by Pfizer of any exclusive therapeutic discovered as a result of the collaboration. The duration of the research collaboration will be 2 years with the option by Pfizer to extend.

AstraZeneca and MAP Pharmaceuticals in worldwide collaboration to develop and commercialize unit dose budesonide

December 19, 2008

AstraZeneca will pay MAP Pharmaceuticals an upfront cash payment of $40 million and an additional $35 million upon the successful achievement of primary endpoint and safety results in the currently ongoing Phase III clinical study. In addition, upon the occurrence of certain events and conditions, MAP Pharmaceuticals is eligible to receive up to $240 million in other potential development and regulatory milestones. The agreement also provides for additional progressively demanding sales performance-related milestone payments of up to $585 million in the event the product is a considerable commercial success.

Ligand enters exclusive license agreement with GlaxoSmithKline for LGD-4665 and other thrombopoietin molecules

December 18, 2008

GlaxoSmithKline will pay Ligand $5 million as an upfront license fee, up to $158 million in development and commercial milestones and a 16% royalty on net sales. In the first year of sales, royalties will be one-half of the regular royalty rate. GlaxoSmithKline has the exclusive right to develop, manufacture and commercialize LGD-4665, as well as other TPO related molecules discovered by Ligand.

DSM Biologics and Crucell in PER.C6 research license agreement with GlaxoSmithKline

December 18, 2008

GlaxoSmithKline (GSK) signed a license agreement allowing GSK to research a recombinant protein on the PER.C6(R) platform. Financial terms of the agreement were not disclosed.

Galapagos extends drug discovery collaboration with Amgen into 2010

December 18, 2008

BioFocus DPI will continue to provide biology, computational and medicinal chemistry services and will supply small molecule compounds for use in Amgen's discovery programs. Under the terms of the extended agreement, Galapagos will receive EUR 2.0 M ($2.55 M) in research fees per year for two years. Additionally, Galapagos is eligible to receive compensation in the form of access fees and success-based milestones.

Pfizer buys rights to market Auxilium's key drug

December 18, 2008

Pfizer to market XIAFLEX (clostridial collagenase for injection) a first-in-class, late-stage biologic, in Europe and other territories for the treatment of Dupuytren's disease and Peyronie's disease. BioSpecifics (Auxilium's partner) will receive $6.375 million of the $75 million upfront payment paid to Auxilium by Pfizer, as well as 8.5% of the $410 million in potential additional milestone payments that may be made by Pfizer to Auxilium. Of these additional milestones, $150 million are tied to regulatory milestones and $260 million are based on sales milestones.

Abbott exercises option to acquire Ibis Biosciences for $215 Million

December 17, 2008

In addition to the closing purchase price, Isis will receive earn out payments from Abbott tied to post-closing sales of Ibis systems, including instruments and assay kits.

Earlier this year, Abbott invested $40 million in Ibis in exchange for approximately 18.6% of Ibis' outstanding equity. This investment, along with the $175 million that would be due at closing, would result in a total acquisition price of $215 million plus earn out payments.

VLST and Novo Nordisk in collaboration to develop therapeutics for autoimmune and inflammatory disorders

December 17, 2008

Novo Nordisk and VLST will jointly undertake a research program to identify collaboration targets and develop product candidates within the field of autoimmune and inflammatory disorders. In exchange for Novo Nordisk’s rights to pursue the targets generated, VLST will receive an upfront payment and equity investment totaling 12 million US dollars, as well as milestone payments which are dependent upon clinical and regulatory milestones across multiple disease indications worldwide. In addition, Novo Nordisk will support the research programs through the committed funding of VLST personnel working on the collaboration targets over the next three years. Novo Nordisk will provide resources to move programs through preclinical development, clinical development and commercialization for each product candidate resulting from the collaboration. The collaboration structure will allow Novo Nordisk to build programs in autoimmunity and inflammation while providing VLST with the ability to develop its own programs that are not part of this collaboration either on its own or with other partners. The research collaboration will run for three years with an option to extend.

GlaxoSmithKline and Dynavax forge drug research deal

December 17, 2008

Dynavax will receive an initial payment of $10 million for which GSK will receive an exclusive option over four programs targeting autoimmune and inflammatory diseases such as lupus, psoriasis, and rheumatoid arthritis.

Dynavax is to conduct research and early clinical development in up to four programs and is eligible to receive future potential development and commercialization milestones totaling approximately $200 million per program. GSK can exercise its exclusive option to license each program upon achievement of proof-of-concept or earlier upon certain circumstances. After exercising its option, GSK will carry out further development and commercialization of these products. Dynavax will receive tiered, up to double-digit royalties on sales and has retained an option to co-develop and co-promote one specified product.

Jexys in strategic R&D collaboration agreement with Teva

December 15, 2008

Teva will finance Jexys' R&D program for the development of a high throughput drug discovery platform and in return will receive a minority equity interest in Jexys Pharmaceuticals. Following the completion of the program, Teva will have the option to in-license 5 drug candidates discovered by Jexys, according to Teva's choice. This agreement is an extension of a collaborative agreement, signed in October 2006 between Jexys and Teva Pharmaceuticals.

HUYA Bioscience in agreement to provide Schering-Plough with drug development candidates from China

December 15, 2008

Schering-Plough has selected HUYA to identify and present to Schering-Plough on an exclusive basis proprietary lead, preclinical and clinical drug candidates in specific therapeutic areas that originate in China. Schering-Plough will gain access to HUYA's growing Chinese bioscience network comprising premier universities, government research institutions and bioparks throughout the country. HUYA already has agreements in place with several of these organizations whereby HUYA has ongoing exclusive access to compounds and biologics in a variety of indications. The company is currently evaluating and following the progress of more than 500 drug development candidates.

Bristol-Myers Squibb to pay $240 million to Exelixis to co-develop two cancer drugs

December 12, 2008

Bristol-Myers Squibb agreed to pay Exelixis an upfront cash payment of $195 million for the development and commercialization rights to both programs and to make additional license payments of $45 million in 2009.

The companies have agreed to co-develop XL184. Exelixis will have the option to co-promote XL184 in the United States. The companies will share worldwide development costs and commercial profits on XL184 in the United States. Exelixis will be eligible to receive sales performance milestones of up to $150 million and double-digit royalties on sales outside the United States. The clinical development of XL184 will be directed by a joint committee. It is anticipated that Exelixis will conduct a significant portion of clinical development activities through 2010. Exelixis may opt out of the co-development of XL184, in which case Exelixis would instead be eligible to receive development and regulatory milestones of up to $295 million, double-digit royalties on XL184 product sales worldwide, and sales performance milestones.

Bristol-Myers Squibb will receive an exclusive worldwide license to develop and commercialize XL281 and will be responsible for funding all future development. Exelixis is eligible for development and regulatory milestones of up to $315 million, sales performance milestones of up to $150 million and double-digit royalties on worldwide sales of XL281.

MIP Technologies enters agreement with Sanofi-Aventis for development of selective separation polymer for biopharmaceuticals

December 10, 2008

MIP Technologies will use a number of its patented molecular imprinting methods in the development of the polymers.

Sanofi-aventis will have exclusive access for use of the polymer in the analysis of proprietary peptide candidates, while MIP Technologies will retain the rights to use the polymers for other applications. The incorporation of the polymer into the sanofi-aventis analytical methods will make use of separation cartridges which will be provided through MIP Technologies' exclusive partnership in analytical products with Supelco, a division of Sigma Aldrich. MIP material developed during the collaboration may also be usable for selective peptide purification at preparative or process scale. Financial terms were not disclosed.

Roche and Axiogenesis enter co-development and marketing deal

December 9, 2008

Financial terms of the contract were not disclosed.

Palatin extends research collaboration and license agreement with AstraZeneca

December 9, 2008

Under the extension to the license agreement, Palatin will receive an upfront payment of $1.6 million and AstraZeneca has been granted licenses to additional compounds and patents. Additionally, the research collaboration term has been extended, with Palatin contributing scientific expertise and AstraZeneca supporting Palatin's internal activities at an agreed full-time equivalent rate.

Under the clinical trial sponsored research agreement, Palatin will be responsible for conducting a study of the effects of melanocortin receptor specific compounds on food intake, obesity and other metabolic parameters. Palatin will be eligible, in the near future, for milestone payments totaling $5 million in connection with the collaboration and license agreement.

Pfizer and Sigma-Tau announce agreement to market a potential new treatment for malaria in Africa

December 9, 2008

Pfizer and Sigma-Tau will ensure access to this novel medicine in Africa in collaboration with the various local stakeholders. Following applicable regulatory submissions and approvals, Pfizer will market the drug in the public and private sectors locally in Africa, and Sigma-Tau will be responsible for the institutional sector. Further details of the financial terms were not disclosed.

BioWa licenses POTELLIGENT technology to GlaxoSmithKline for use in antibody development

December 8, 2008

BioWa will provide GSK with non- exclusive commercial rights to use the technology for multiple antibodies. In return, BioWa will receive technology access fees, and may receive milestone payments and royalties from resulting products which are developed by GSK. Additional terms were not disclosed.

BMS and AstraZeneca expand diabetes tie-up to Japan

December 8, 2008

In January 2007, Bristol-Myers Squibb and AstraZeneca entered into a global collaboration, excluding Japan, to enable the companies to research, develop and commercialize dapagliflozin. The companies now have agreed to co-develop dapagliflozin in Japan with AstraZeneca having operational and cost responsibility for all development and regulatory activities on behalf of the collaboration. The two companies will jointly market the product in Japan, sharing all commercialization expenses and activities and splitting profits/losses equally. Bristol-Myers Squibb will manufacture dapagliflozin and also book sales.

Ascent and Novartis Option Fund enter licensing option agreement for select Pepducin drug candidates

December 8, 2008

Ascent will discover and develop Pepducin drug candidates against a specific GPCR target. The agreement includes an upfront fee and potential milestones totaling over $200 million as well as royalties.

ImmunoGen announces Genentech’s fifth TAP technology license

December 8, 2008

This license was taken under an agreement established between the companies in 2000. It grants Genentech the exclusive right to use ImmunoGen’s maytansinoid TAP technology with Genentech’s therapeutic antibodies to the undisclosed target to develop anticancer therapeutics. Under the terms of the license, ImmunoGen receives a $1 million license payment upfront and is entitled to receive milestone payments plus royalties on the sales of any resulting products. Genentech is responsible for the development, manufacturing, and marketing of any products resulting from this license.

BTG completes acquisition of Protherics

December 4, 2008

All the conditions to its recommended offer for Protherics have been satisfied and the acquisition has therefore been completed.

Evotec in 3-year drug discovery collaboration with Novartis

December 3, 2008

Evotec will apply its powerful drug discovery platform in combination with its extensive disease biology expertise to advance a drug discovery program against a target nominated by Novartis through discovery into the clinic. Furthermore, the agreement may be expanded by the addition of a second program.

Under the terms of the agreement, Evotec will progress the programs up to preclinical development and Novartis will then have the responsibility for all clinical development activities, manufacture and commercialization of the compounds. In return for Evotec's contributions to the research program, Evotec is eligible for an upfront payment, research funding as well as preclinical and clinical milestone payments that could exceed $28 million. In addition, Novartis will pay royalties on sales of any marketed products resulting from the collaboration.

Cell Genesys and Takeda terminate collaboration agreement for GVAX immunotherapy

December 3, 2008

Mutually agreed to suspend the further development of GVAX immunotherapy for prostate cancer and that Takeda has ended the collaboration agreement with Cell Genesys for the development and commercialization of the product.

Under the terms of the agreement, Takeda will return all commercial rights to GVAX immunotherapy for prostate cancer to Cell Genesys and make certain wind-down payments to Cell Genesys in connection with the phasing out of the remaining clinical development activities.

DxS and Amgen enter collaboration to provide a K-RAS companion diagnostic for Vectibix in USA

December 2, 2008

DxS and Amgen shall work together to further facilitate the use of Vectibix® in metastatic colorectal cancer patients with wild-type K-RAS status in the United States, with the intent that DxS’ TheraScreen: K-RAS Mutation Kit will become a companion diagnostic for use with Vectibix® if approved by the FDA. This agreement between Amgen and DxS follows a collaboration entered into by the parties last year with respect to the TheraScreen: K-RAS Mutation Kit in Europe.

Mylan and Novartis agree settlement on Femara generic

December 2, 2008

Mylan is provided a patent license that will enable the company to market Letrozole Tablets, 2.5 mg, prior to the expiration of U.S. Patent No. 4,978,672. Additional terms related to the settlement remain confidential, and the agreement is subject to review by the U.S. Department of Justice and the Federal Trade Commission.

Paladin Labs and GlaxoSmithKline sign agreement on Dexedrine

December 1, 2008

GlaxoSmithKline appoints Paladin Labs as exclusive distributor of Dexedrine within Canada for a period of three years, with an option for Paladin to purchase all remaining rights to the product in Canada at the end of that period.

GSK will be providing certain distribution support services for an interim period. The agreement also marks the start of a strategic relationship with GSK whereby Paladin Labs Inc. will have the first right to partner with GSK on a number of products that GSK may choose to license or divest in Canada. Financial terms of the transaction were not disclosed.

ProStrakan licenses testosterone gel to Bayer Schering Pharma

December 1, 2008

Exclusive license to Bayer Schering Pharma to develop and market its testosterone replacement gel Tostran in 65 countries for an undisclosed amount.

The company said it would also get royalties and certain delayed payments on the product meeting some sales targets.

Bayer Schering will make unspecified upfront and milestone payments to ProStrakan as per the agreement.

Johnson & Johnson to acquire Mentor

December 1, 2008

Johnson & Johnson will commence a tender offer to purchase all outstanding shares of Mentor at $31.00 per share. The tender offer is conditioned on the tender of a majority of the outstanding shares of Mentor's common stock on a fully diluted basis. The closing is conditioned on clearance under the Hart-Scott-Rodino Antitrust Improvements Act, and other customary closing conditions. The $1.12 billion estimated net value of the transaction is based on Mentor's 34.6 million fully diluted shares outstanding, plus estimated net debt at time of closing. The boards of directors of Johnson & Johnson and Mentor have approved the transaction.

November

Compugen and Merck Serono to collaborate on novel peptide for treatment of inflammatory diseases

November 26, 2008

The agreement covers additional research to be conducted by Compugen and provides Merck Serono with an option to exclusively license the novel peptide for worldwide development and commercialization.

AstraZeneca and Abraxis to end cancer drug deal

November 25, 2008

Agreement with AstraZeneca, under which, subject to approval by the board of directors of Abraxis, the company would re-acquire the exclusive rights to market Abraxane in the USA.

Roche signs agreement to acquire Memory

November 25, 2008

The two companies have signed a definitive merger agreement for Roche to acquire all the outstanding shares of Memory Pharmaceuticals in an all-cash transaction for an aggregate price of approximately USD 50 million.

Watson acquires 17 generic drugs from Teva-Barr deal

November 25, 2008

Watson will acquire the portfolio of products for an upfront payment of $36 million and will make additional payments to Teva when certain milestones are met on the development-stage products. Teva will supply the products to Watson under a Manufacturing and Supply Agreement until manufacturing is transferred to Watson or a third party.

TorreyPines enters agreement to reduce royalty rates and delay milestone payments due to Eli Lilly for NGX426 and Tezampanel

November 25, 2008

Specifically, the top tier royalty rate will be reduced three percentage points and the middle tier royalty rate will be reduced one half percentage point. The bottom tier royalty rate will remain unchanged. In addition, certain milestone payments due to Eli Lilly related to the clinical development of NGX426 will be delayed from what was originally agreed. In exchange for the royalty rate reduction and change in milestone payment timing, TorreyPines issued to Eli Lilly two hundred thousand shares of TorreyPines Common Stock at fair market value. TorreyPines originally licensed NGX426 and tezampanel from Eli Lilly in April 2003.

King to acquire Alpharma for approximately $1.6 billion

November 24, 2008

Definitive merger agreement under which King will acquire all of the outstanding shares of Class A Common Stock of Alpharma for $37.00 per share in cash for a total equity value of approximately $1.6 billion. The Boards of Directors of both companies have unanimously approved the transaction.

Johnson & Johnson acquire Omrix for $438 million

November 24, 2008

Definitive agreement whereby Omrix will be acquired for approximately $438 million in a cash tender offer. Omrix is expected to operate as a stand-alone entity reporting through ETHICON, a Johnson & Johnson company.

Under the terms of the agreement, Johnson & Johnson will commence a tender offer to purchase all outstanding shares of Omrix at $25.00 per share, which is expected to close by the end of December 2008. The tender offer is conditioned on the tender of a majority of the outstanding shares of Omrix's common stock on a fully diluted basis. The closing is conditioned on Israeli antitrust clearance and other customary closing conditions. The $358 million estimated net value of the transaction is based on Omrix's 17.5 million fully diluted shares outstanding, net of estimated cash on hand at time of closing.

Exelixis to co-develop cancer therapy with BMS

November 24, 2008

Under the terms of the agreement, Exelixis is fully responsible for the identification and preclinical development of small molecule drug candidates directed against mutually selected targets. In addition to an upfront payment of $60 million in January 2007, the agreement provides for Exelixis to receive $20 million for each of up to three different IND-stage drug candidates selected by Bristol-Myers Squibb. For each candidate selected by Bristol-Myers Squibb, Exelixis has the right to opt in to the co-development or co-promotion in the United States.

If Exelixis does not opt in to co-promote the selected IND candidates, Exelixis would be entitled to receive milestones and royalties in lieu of profits from sales in the United States. Outside of the United States, Bristol-Myers Squibb will have primary responsibility for development activities and Exelixis will be entitled to receive royalties on product sales.

Eli Lilly completes acquisition of ImClone

November 24, 2008

As a result of the merger, all outstanding shares of ImClone common stock not purchased by Lilly in the tender offer were converted into the right to receive $70.00 per share in cash.

GlaxoSmithKline signs pre-JV vaccine pact with Shenzhen Neptunus Interlong Bio-Techique

November 21, 2008

GlaxoSmithKline and Shenzhen Neptunus Interlong Bio-Technique will work together to develop flu vaccines for the China market. The two companies have signed a formal Cooperation Agreement that will lead to the formation of a JV company with $78 million of assets, if certain undisclosed conditions are met.

Infinity in global strategic alliance with Purdue and Mundipharma

November 20, 2008

The alliance will focus on the advancement of Infinity's early-stage clinical and discovery pipeline of novel, small molecule drug candidates. This pipeline includes IPI-926, Infinity's potent inhibitor of the Hedgehog pathway. IPI-926 is being evaluated in a Phase 1 clinical study in patients with advanced solid tumors and has demonstrated significant anti-tumor activity in a number of preclinical models. Infinity's pipeline also includes several earlier stage discovery programs, including a program directed to fatty acid amide hydrolase (FAAH), an emerging target for the treatment of neuropathic pain.

Karo Bio and Wyeth collaboration targets inflammation

November 20, 2008

The collaboration with Wyeth has primarily been focused on atherosclerosis but other clinical opportunities have also been explored. The continued collaboration will focus on drug discovery in the field of inflammatory diseases.

Idera and Merck extend research collaboration for agonists of toll-like receptors

November 20, 2008

As part of the agreement, the two companies engaged in a two-year research collaboration to generate novel agonists targeting TLR7 and TLR8 incorporating both Merck and Idera chemistry for use in the licensed fields.

Stem Cell Sciences signs service agreement with Pfizer to provide access to proprietary technologies and methods

November 20, 2008

Under the terms of the agreement, SCS will provide research services, cell lines, media and reagents to support Pfizer's R&D efforts in this important field.

Galapagos and Merck Serono enter new collaboration agreements

November 18, 2008

Total value of the contracts for Galapagos is EUR 1.1 million over one year.

Galapagos' service division BioFocus DPI will provide SoftFocus© compounds for use in Merck Serono's drug discovery programs. In a separate agreement, BioFocus DPI will perform medicinal chemistry services on an undisclosed Merck Serono program; this represents an extension of a long running collaboration which was last expanded in 2005.

Genzyme and International Center for Genetic Engineering and Biotechnology form collaboration to advance treatments for neglected diseases

November 18, 2008

The collaboration between Genzyme and ICGEB will initially focus on the development of new, improved treatments for malaria, a debilitating infectious disease of developing countries.

Eli Lilly selects ICON to manage clinical data management business outside USA

November 18, 2008

The agreement, which spans more than three dozen countries, excluding the United States and Japan, will help to transform Lilly’s research and development organisation as they seek to drive productivity, gain speed to market and lower drug development costs.

Life Science Pharmaceuticals enters agreement with Abbott to develop antibody

November 17, 2008

The agreement provides Abbott with exclusive worldwide rights to Antibody 806, which targets the clinically validated pathway involving the Epidermal Growth Factor receptor (EGFr). Antibody 806 is differentiated by its unique epitope targeting a transitional form of EGFr. Financial details of the agreement were not disclosed.

Eli Lilly licenses US rights for Tadalafil PAH indication to United Therapeutics

November 17, 2008

United Therapeutics will make an upfront payment of $150 million to Lilly for the exclusive rights to commercialize tadalafil for PAH in the United States, as well as for a product manufacturing and supply arrangement. Lilly will manufacture and supply tadalafil to United Therapeutics and will retain authority globally for all regulatory, development, intellectual property and manufacturing aspects of the tadalafil molecule for all potential indications. Lilly will also retain commercialization rights to tadalafil for PAH outside of the U.S. In addition, Lilly will purchase $150 million of common stock from United Therapeutics. The transaction is subject to clearance of the stock purchase under the Hart-Scott-Rodino Antitrust Improvements Act and other customary closing conditions.

Genentech licenses ex-US rights to GDC-0449 to Roche

November 13, 2008

Roche received this license pursuant to an agreement between Genentech and Roche under which Genentech granted Roche an option to obtain a license to commercialize certain Genentech products in non-U.S. markets.

Redpoint Bio signs research agreement with Schering

November 13, 2008

This expanded feasibility agreement builds upon the successful completion of a previous research study between the parties. Scope and terms of the agreement were not disclosed.

ADMETRx and Roche collaborate on multicriteria decision-making application

November 13, 2008

ADMETRx and Roche both recognize how comprehensive data integration may offer significant advantages to discovery groups in selecting candidates for advancement.

Biovitrum extends ReFacto supply agreement with Wyeth until 2015

November 12, 2008

Biovitrum will continue to be the sole producer of drug substance for Wyeth for ReFacto, as well as Xyntha/ReFacto AF, the successor products, and will continue to receive royalties from Wyeth's global sales. Biovitrum's co-promotion rights in the Nordic region remain unchanged.

Antyra enters licensing deal for anticancer agents from Novo Nordisk

November 12, 2008

ANTYRA will obtain exclusive rights to develop and commercialize certain IGF antagonists discovered during the Research and License Collaboration Agreement entered into between the Companies in December 2001. Financial terms of the agreement were not disclosed.

Almirall to sell Pfizer hypertension drug In Spain

November 11, 2008

The drug is due to be launched in Spain in the first quarter of 2009.

TorreyPines sells Alzheimer's disease genetics program to Eisai

November 10, 2008

TorreyPines and Eisai have collaborated on the genetics program since 2002, with the most recent agreement between the parties concluding on September 30, 2008. The Alzheimer's disease genetics research program focused on the discovery of Alzheimer's disease targets using whole-genome family-based association screening.

XOMA restructures drug development collaboration with Novartis Vaccines & Diagnostics

November 10, 2008

Under the restructured agreement Novartis will make an upfront payment to XOMA of $6.2 million; fully fund all future R&D expenses; reduce existing debt by $7.5 million; pay potential milestones of up to $14 million and double-digit royalty rates for two ongoing product programs including HCD122; and provide XOMA with options to develop or receive royalties on four additional programs currently pending selection.

In exchange, Novartis will have control over the HCD122 program and the additional ongoing program, as well as the right to expand the development of these programs into additional indications outside of oncology. As part of the agreement, NVS will pay XOMA for all project costs incurred after July 1.

ArQule and Daiichi Sankyo enter strategic R&D partnership to progress compounds targeting cancer

November 10, 2008

ArQule and Daiichi Sankyo have entered into a binding letter of intent for an exclusive license, co-development and co-commercialization agreement under which they shall collaborate to conduct research, clinical trials and the market launch of ARQ 197 in human cancer indications in the U.S., Europe, South America and the rest of the world, excluding Japan, China (including Hong Kong), South Korea and Taiwan, where Kyowa Hakko Kirin Co., Ltd. (Kyowa) has exclusive rights for development and commercialization.

The binding letter of intent provides for a $60 million cash upfront licensing payment from Daiichi Sankyo to ArQule. In addition, the binding letter of intent includes significant development and sales milestone payments. ArQule and Daiichi Sankyo will share equally the costs of Phase 2 and Phase 3 clinical studies, with ArQule’s share of Phase 3 costs payable solely from milestone and royalty payments by Daiichi Sankyo. Upon commercialization, ArQule will receive tiered royalties from Daiichi Sankyo on net sales of ARQ 197.

ArQule and Daiichi Sankyo have also entered into a research collaboration, exclusive license and co-commercialization agreement under which ArQule will apply its proprietary technology and know-how from its AKIP™ platform for the discovery of therapeutic compounds that selectively inhibit certain kinases. The agreement defines two such kinase targets, and Daiichi Sankyo will have an option to license compounds directed to these targets following the completion of certain pre-clinical studies.

The agreement provides for a $15 million upfront payment, undisclosed payments in research support for the first and second years of the collaboration, licensing fees for compounds discovered as a result of this research, milestone payments related to clinical development, regulatory review and sales, and royalty payments. ArQule retains the option to co-commercialize licensed products in the U.S.

WuXi PharmaTech signs new collaboration with Pfizer

November 7, 2008

Under the new collaboration agreement WuXi PharmaTech in partnership with Pfizer will establish ADME assays to provide in vitro screening services on compounds WuXi PharmaTech synthesizes for Pfizer.

Winston Laboratories announces licensing agreement with Sanofi-Aventis in Canada

November 7, 2008

Under the terms of the agreement, sanofi-aventis Canada Inc. owns the rights to develop, manufacture and commercialize civamide cream in Canada along with a second generation cream that is currently in development. In return for granting sanofi-aventis Canada Inc. the Canadian rights, Winston will receive an upfront payment, a milestone payment subject to regulatory approval of civamide cream in Canada plus royalties and milestones on net sales in Canada.

Cabernet and Eli Lilly form pharmacogenetics alliance to help deliver tailored therapeutics to patients

November 6, 2008

Under the agreement, Cabernet consultants will join clinical-development teams at Lilly to assist in applying pharmacogenetics to selected development projects. Financial terms were not disclosed.

Exelixis research collaboration with Bristol-Myers Squibb extended

November 6, 2008

The collaboration, originally established in January of 2006 for a period of two years, was extended in 2007, at Bristol-Myers Squibb's request, through January 12, 2009. Bristol-Myers Squibb has now exercised its option to further extend the research collaboration by an additional year to January 12, 2010. Terms of this extension include additional research funding paid to Exelixis in the amount of $6.0 million.

Celera and Abbott enter collaboration to identify pharmacogenomic markers

November 5, 2008

Abbott will pay Celera an undisclosed fee to perform this study and any resulting companion diagnostic product could be developed by Celera and commercialized through its existing strategic alliance with Abbott.

Osiris Therapeutics and Genzyme enter stem-cell deal

November 4, 2008

Osiris will commercialize Prochymal and Chondrogen in the United States and Canada, and Genzyme will commercialize the treatments in all other countries. Genzyme will make an up-front payment of $130 million to Osiris, plus potential significant milestone and royalty payments.

Thermo Fisher Scientific to collaborate with Genentech on novel technology enabling development of siRNA therapeutics

November 4, 2008

Thermo Fisher Scientific will provide Genentech with siRNA design, stabilization, delivery and related RNA interference (RNAi) technologies from its RNAi Discovery and Therapeutic Services laboratory in Lafayette, Colorado. Genentech may use these technologies in the development of potential siRNA-based drugs. Such drugs would work by reducing, or silencing, the expression of specific genes implicated in disease. The research could extend drug discovery efforts to disease targets where traditional discovery technologies have not been successful.

Acusphere closes financing with Cephalon

November 3, 2008

Cephalon will provide Acusphere with $20 million in immediate financing through the issuance of a $15 million senior secured convertible note and a $5 million upfront fee for an exclusive worldwide license to AI-525, a preclinical-stage injectable formulation of celecoxib using Acusphere’s proprietary Hydrophobic Drug Delivery System (HDDS) technology.

Daiichi Sankyo acquires Merck Serono's cardio-metabolism sales force and products in Turkey

November 3, 2008

It is the second agreement that DAIICHI SANKYO and Merck have reached in recent weeks. In August, the Japanese pharmaceutical company obtained the sales force of Merck Pharma GmbH that served primary-care physicians in Germany.

October 2008

Biogen and Genentech partner to develop new blood cancer drug

October 31, 2008

Biogen Idec and Genentech will share certain development costs. Biogen Idec will make an upfront payment to Genentech of $31.5 million, which will be recorded as a research-and-development expense in the fourth quarter of 2008. Biogen Idec and Genentech will share operating profits and losses in the United States. Roche retains commercialization rights outside the United States. Additional financial and other terms were not disclosed.

GlaxoSmithKlineacquires Genelabs Technologies

October 30, 2008

GSK will acquire Genelabs for approximately $57 million (£35 million) through a tender offer of $1.30 per share in cash. This strategic acquisition will strengthen GSK’s effort to develop and deliver novel therapies against the hepatitis C virus (HCV).

Under the terms of the agreement, a subsidiary of GSK will commence a tender offer to acquire all of the outstanding shares of Genelabs common stock. The board of directors of Genelabs has unanimously recommended that shareholders tender their shares in the offer.

Lpath and Merck Serono form alliance for Asonep

October 29, 2008

Merck Serono will provide Lpath up to $23 million of upfront payments and R&D funding to support Lpath's completion of the Phase 1 clinical trial. If Merck Serono accepts the responsibility to develop ASONEP beyond Phase 1, it will pay Lpath an additional $28 million and will fund all continuing development activities. Further payments will be made on achievement of development, regulatory, and sales milestones that could total up to $422 million should ASONEP be approved in multiple indications.

As part of the alliance, Lpath licensed to Merck Serono exclusive, worldwide rights to develop and commercialize ASONEP across all indications, and Lpath will receive royalties on commercial sales of the product.

Theratechnologies and EMD Serono in collaboration and licensing deal for Ttesamorelin

October 29, 2008

Theratechnologies will receive an upfront payment of US$30 million (CAD$38.7 M) which includes a license fee of US$22 million (CAD$ 28.4 M) and an equity investment of US$8 million (CAD$10.3 M) in Theratechnologies common stock at a price of US$3.67 (CAD$ 4.73) per share by Merck KGaA, providing Merck KGaA a 3.6% ownership in Theratechnologies. Theratechnologies may receive up to US$215 million (CAD$277 M) in total payments, including the upfront payment, and payments based on the achievement of certain development, regulatory and sales milestones. Theratechnologies will be entitled to receive increasing royalties on annual net sales of tesamorelin in the US.

Theratechnologies will be responsible for conducting research and development for additional indications. EMD Serono will have the option to co-develop and commercialize additional indications for tesamorelin in the US. EMD Serono will equally share in the development costs related to such additional indications if it exercises its option. Theratechnologies will, in such case, also have the right, subject to EMD Serono's agreement, to opt to co-promote such additional indications.

Allergan and Spectrum in collaboration agreement for Apaziquone

October 29, 2008

Allergan will pay Spectrum $41.5 million at closing and will make additional payments of up to $304 million based on the achievement of certain development, regulatory and commercialization milestones. Spectrum retained exclusive rights to apaziquone in Asia, including Japan and China. Allergan received exclusive rights to apaziquone for the treatment of bladder cancer in the rest of the world, including the United States, Canada and Europe.

In the United States, Allergan and Spectrum will co-promote apaziquone and share in its profits and expenses. Allergan will also pay Spectrum royalties on all of its apaziquone sales outside of the United States. Spectrum will continue to conduct the apaziquone clinical trials pursuant to a joint development plan, with Allergan bearing the majority of these expenses.

AstraZeneca and M. D. Anderson Cancer Center renew cancer research alliance

October 29, 2008

The collaboration facilitates interactions between physicians and scientists in both organizations to combine resources and expertise in disease intervention whilst providing flexibility to work in a variety of ways and accelerate the development of new treatments. It is unusual in its focus on pre-clinical research and the transition to clinical trials and was the first of its kind for both institutions.

Since its launch in 2005, the collaboration has utilized AstraZeneca's early development portfolio to generate over two dozen joint research projects. Both parties intend to build on these by extending the collaboration for a further five years and broadening its original focus from aerodigestive diseases (head and neck cancers and lung cancer) to include targets with potential in a variety of cancer settings.

Antitope in antibody research agreement with Boehringer Ingelheim

October 29, 2008

Antitope will apply its proprietary Composite Human AntibodyTM technology for the humanization of Boehringer Ingelheim's therapeutic antibodies.

Johnson & Johnson establishes Wellness & Prevention platform with acquisition of HealthMedia

October 28, 2008

Terms of the transaction were not disclosed.

Graffinity and AstraZeneca enter multi-target drug discovery alliance

October 28, 2008

Graffinity will receive technology access fees, success dependent milestone payments and optional payments for follow-on projects. The focus of the collaboration will be the generation of multiple novel small molecule hit series against a variety of drug targets from diverse therapeutic areas.

Graffinity will apply its proprietary fragment-based drug discovery technology and drug fragment chemical microarrays to identify small molecule hit structures focusing on compounds with novel modes of action. Financial details of the transaction were not disclosed.

GlaxoSmithKline to market Valeant's seizure drug

October 24, 2008

GlaxoSmithKline will market the drug to U.S. doctors in 2009, and the pact can be extended if both companies agree to do so. Terms of the deal were not disclosed.

Amgen signs IBM services deal Worth

October 24, 2008

Amgen hired IBM to provide technology services in a deal worth as much as $800 million over eight years.

AstraZeneca and Cognizant announce five-year deal

October 23, 3008

The agreement will further expand Cognizant's long-standing relationship with the pharmaceutical major.

Under the expanded agreement, Cognizant will work with AstraZeneca's Global Shared Services organization and implement world class, end-to-end application maintenance services. As part of this innovative agreement, Cognizant will adopt an "Outcome" or "Effect-based" model to provide these services by leveraging its global delivery network, talent pool and best practices. This will ensure a predictable service model, reduce the overall cost of IT ownership, and deliver year-over-year efficiency improvements.

Forest and Phenomix Corporation in diabetes deal

October 23, 2008

Forest will make an upfront payment to Phenomix of $75 million. Phenomix and Forest will jointly develop and commercialize dutogliptin in the United States, and the companies will equally share profits and expenses. Upon commercialization, the parties will co-promote the product in the United States, with Phenomix promoting dutogliptin to endocrinologists and diabetologists and Forest promoting to primary care and specialty physicians.

Forest has exclusive rights to develop and commercialize dutogliptin in Canada and Mexico, and Phenomix will receive a royalty on sales in these countries in exchange for the rights to use jointly funded trial data in those countries. Phenomix retains development and commercialization rights to the product outside of North America, and will pay Forest a royalty on net sales in these territories. Phenomix could receive up to $340 million in upfront and milestone payments for the successful development and commercialization of dutogliptin in the United States over the term of the collaboration.

Exelixis-GlaxoSmithKline collaboration to end

October 23, 2008

GlaxoSmithKline (GSK) (LSE: GSK - News; NYSE: GSK - News) has decided not to exercise its option to license XL184. GSK also informed Exelixis that it had decided not to license the earlier compounds in the collaboration, including XL281, XL228, XL820, and XL844. As a result, Exelixis retains the rights to develop, commercialize, and/or license all of the compounds, subject to payment to GSK of a 3% royalty on net sales of any product incorporating XL184.

With GSK’s decision not to exercise an option to any of the compounds, the six-year collaboration between Exelixis and GSK to discover and develop oncology compounds comes to an end.

GlaxoSmithKline and AFFiRiS ink Alzheimer vaccine deal

October 23, 2008

As part of the agreement GSK is acquiring exclusive rights to develop and commercialise two Alzheimer's disease vaccine candidates that are based on AFFiRiS AFFiTOPE technology and are currently in Phase I clinical development. AFFiRiS is also granting GSK an exclusive option to develop and commercialise alternative Alzheimer's disease vaccine candidates which are in preclinical development.

Under the terms of the agreement, AFFiRiS will receive an up-front payment of EUR 22.5 million (GBP17.5 million) and could be eligible for future milestone payments and royalties. The total potential value of the agreement could reach EUR 430 million (GBP334 million) in the event of full commercial success of the candidate vaccines. This agreement is subject to governmental authority approval.

Eli Lilly and Amylin enter supply agreement for Exenatide once weekly

October 22, 2008

Lilly will make an initial cash payment of $125 million to Amylin, and Amylin will supply product for sales in the U.S. and to Lilly for sales outside of the U.S. In addition to the $125 million upfront payment, Lilly will reimburse Amylin for its share of the more than $500 million capital investment in the West Chester, Ohio facility through the cost of goods sold for exenatide once weekly.

As part of the overall supply arrangement, Lilly will make available to Amylin a $165 million line of credit that Amylin can draw upon beginning in the fourth quarter of 2009 through the second quarter of 2011. Any debt from the credit facility will be due three years from the date that the full amount has been drawn or the second quarter of 2014, whichever occurs first.

Bayer licenses rights to TAP technology for from Immunogen

October 21, 2008

Bayer HealthCare receives exclusive worldwide rights to develop anticancer compounds to the target using ImmunoGen’s maytansinoid cell-killing agents and linker technology. Bayer HealthCare is responsible for the research, development, manufacturing and marketing of products resulting from this license.

ImmunoGen will receive an upfront payment of $4 million. For each compound developed and marketed by Bayer under this collaboration, ImmunoGen is entitled to milestone payments potentially totaling $170.5 million plus royalties on commercial sales. ImmunoGen also is entitled to receive financial compensation for the production of any preclinical and non-pivotal clinical materials and for any product development research done on behalf of Bayer HealthCare.

Roche confirms Genentech bid

October 21, 2008

Swiss drugmaker Roche confirmed its commitment to a $43.7 billion bid for the rest of Genentech.

Nektar Therapeutics sells pulmonary business to Novartis

October 21, 2008

Novartis will assume ownership of certain dry powder and liquid pulmonary formulation and manufacturing assets, including capital equipment and manufacturing facility capital lease obligations. The agreement also transfers to Novartis approximately 140 Nektar personnel, as well as certain intellectual property and manufacturing methods. Additionally, Nektar will transfer manufacturing and royalty rights to the Tobramycin inhalation powder (TIP) program, already partnered with Novartis.

GlaxoSmithKline to acquire leading dry mouth brand, Biotene

October 21, 2008

GlaxoSmithKline Consumer Healthcare has reached an agreement with Laclede to purchase the leading Dry Mouth brand Biotene for $170 million.

Nerviano Medical Sciences in deal with Genentech to discover antibody drug conjugates

October 21, 2008

Terms of the multi-year collaboration include an initial one-time-license-fee, milestones and royalties for licensed products as well as milestones on a target-by-target basis. Further details and financial terms were not disclosed.

Sartorius Stedim Biotech and Bayer Technology Services form alliance

October 20, 2008

With the technology developed by BTS, viruses are inactivated in biopharmaceuticals by UVC irradiation. Typical areas of use are virus inactivation of cell culture media, antibody solutions and solutions containing recombinant proteins as well as irradiation of vaccines and therapeutics produced from blood and plasma. Further areas of application, such as removal of mycoplasma from bioreactor media, are currently being assessed.

Archemix signs aptamer therapeutics agreement with Eli Lilly

October 20, 2008

The agreement enables Archemix to license certain intellectual property rights from Lilly and, in return, Lilly has an option to conduct R&D evaluation of aptamers for certain drug targets. Lilly also retains an option to enter into an exclusive license with Archemix for up to two of the aptamer targets.

Valeant and GlaxoSmithKline complete worldwide collaboration agreement for Retigabine

October 17, 2008

Valeant received an upfront payment of $125 million from GSK.

Daiichi Sankyo buys twenty percent stake in Ranbaxy

October 17, 2008

Daiichi's payment for the 20 percent stake it obtained from the market had been postponed due to a delay in approval by Indian authorities.

As part of the deal to acquire a stake of at least 50.1 percent and estimated at $4.6 billion, it also plans to buy an 34.8 percent holding from Ranbaxy's founding family, as well as new shares.

It paid a total 68.2 billion Indian rupee ($1.4 billion), or 737 rupee per share, for the 20 percent holding plus interest amounting nearly 1 billion yen due to the payment delay.

MedImmune licenses reverse genetics technology to Hungary's Omninvest

October 16, 2008

MedImmune will receive an upfront payment and has the potential to receive royalties on certain vaccine stockpiles or sales of other influenza products developed using the reverse genetics technology.

Alcon expands licensing agreement with GlaxoSmithKline

October 15, 2008

Terms of the agreement with GSK include an upfront payment, with additional payments to GSK based on the achievement of developmental milestones and the receipt of ophthalmic product approvals incorporating cilomilast. Royalties will be paid to GSK on the future sales of products incorporating the compound. GSK retains all rights to cilomilast for applications outside of ophthalmic indications and a right to co-promote cilomilast to some physicians for ophthalmic indications.

InforSense collaborates with GlaxoSmithKline and industry innovators to enable virtual drug discovery

October 15, 2008

The project is sponsored by SIMDAT -- a program funded by the European Commission under the Information Society Technologies Programme (IST) designed to test and enhance Grid data technology for product development and production process design.

Alcon expands drug research alliance with Origenis for the treatment of eye diseases

October 15, 2008

The terms of the agreement provide that Alcon will retain the rights to any products for ophthalmic and nasal applications and Origenis will retain certain rights to all other uses of drug candidates discovered during the alliance. Alcon will make research payments to Origenis through a series of development milestones and royalties on sales.

AstraZeneca and Columbia University Medical Center in strategic research collaboration in neurosciences

October 15, 2008

Neurogenesis -- the creation of new neuronal cells - in adults might offer novel approaches to treating depression and anxiety.

TB Alliance in collaboration with Sanofi-Aventis K.K. to fight tuberculosis

October 15, 2008

Under the agreement, the two organizations will share information on their respective projects and exchange insights on developments in TB drug research. Additionally, they will consult with each other on relevant regulatory, access, and clinical trial capacity strategies related to developing countries. These activities may open new avenues of possible common development in the future.

GlaxoSmithKline expands in Egypt with acquisition from Bristol-Myers Squibb

October 15, 2008

Glaxo said it will become the leading pharmaceutical company in Egypt with a market share of 9 percent by acquiring 20 branded products in four therapeutic disease areas, including Duricef (antibiotic); Capozide and Capoten (ACE inhibitors); Theragran-H (iron supplement) and Kenacomb (topical steroid).

Eli Lilly commences cash tender offer for ImClone Systems

October 14, 2008

Eli Lilly announced that its wholly-owned subsidiary, Alaska Acquisition Corporation, has commenced its tender offer for all outstanding shares of ImClone Systems Incorporated at a price of $70.00 net per share in cash. Lilly and ImClone previously announced that they had reached a definitive merger agreement for Lilly to acquire ImClone.

King extends tender offer to acquire Alpharma

October 13, 3008

King has extended its previously announced tender offer for all outstanding shares of Class A Common Stock of Alpharma November 21, 2008.

Novo Nordisk assigns inhaled insulin patent portfolio to Aradigm

October 9, 2008

Novo purchased a significant portion of the portfolio from Aradigm in July 2006 and supplemented the portfolio with certain of its own related patents. The portfolio includes both U.S. and foreign patents. Aradigm assumes responsibility for the maintenance of this portfolio.

Tripos enters collaborate on molecular invention workflow for drug discovery with AstraZeneca

October 8, 2008

The centerpiece of the collaboration effort will be the development of Tripos' new Muse de novo design product, which is targeted for commercial release in the fourth quarter of 2008.

Takeda licenses recombineering technology from Gene Bridges

October 7, 2008

Commercial license agreement for the use of the Red/ET recombination technology.

National Comprehensive Cancer Network, Abraxis BioScience and AstraZeneca in collaboration to conduct anti-cancer drug studies

October 6, 2008

The NCCN studies will evaluate ABRAXANE in the treatment of breast, non-small cell lung, head and neck, melanoma and ovarian cancers.

Abraxis and AstraZeneca, which have a co-promotion agreement for marketing ABRAXANE in the United States, are providing funding in support of the clinical studies.

Eli Lilly to buy ImClone Systems for $6.5 billion

October 6, 2008

Definitive merger agreement under which Lilly will acquire ImClone through an all cash tender offer of $70.00 per share, or approximately $6.5 billion. The offer represents a premium of 51 percent to ImClone's closing stock price on July 30, 2008.

Covance and Eli Lilly in 10-year strategic R&D collaboration

October 6, 2008

Covance to provide a broad-range of drug development services over the next ten years and to purchase Lilly's 450-acre early drug development campus in Greenfield, Indiana.

Opko Health acquires worldwide ophthalmic rights to Teva

October 3, 2008

Teva’s proprietary formulation of budesonide for the treatment of various inflammatory and allergic conditions of the eye. Teva’s proprietary budesonide product is currently marketed in Italy under the tradename XAVIN for the treatment of asthma.

Genentech, Glycart and Roche in collaboration agreement

October 3, 2008

The companies will be developing GA101, a humanized anti-CD20 monoclonal antibody engineered to increase both direct- and immune-mediated target cell death, for the potential treatment of hematological malignancies and other oncology-related B-cell disorders such as non-Hodgkin’s lymphoma.

In association with this agreement, Genentech, Roche and GlycArt will share certain development costs and Genentech will record $105 million in research and development expense in its third quarter 2008 results. Genentech will receive commercialization rights in the United States.

Eli Lilly and Deciphera in licensing and collaboration deal

October 3, 2008

The collaboration will apply Deciphera's phylomechanics discovery platform, a unique, proprietary approach to kinase inhibitor design, together with Lilly's expertise in discovery, development and commercialization to pursue first-in-class and best-in-class drug candidates for a variety of cancers.

Under the terms of the agreement, Lilly and Deciphera will collaborate in four different project areas involving selective or multi-kinase targeted B-Raf inhibitors. Lilly will obtain exclusive worldwide rights to any products developed as part of this collaboration.

In return, Deciphera will receive an upfront payment and research funding over the next two years from Lilly, and may also receive up to $130 million in potential development, regulatory and sales milestones for each of the four project areas. If a product is successfully commercialized from this collaboration, Deciphera will be entitled to royalties on sales.

Meda acquisition of product portfolio from Roche completed

October 2, 2008

The acquired products have strong brand names and the total sales level is 500 MSEK. No employees will transfer from Roche to Meda in conjunction with the acquisition. Meda acquires world-wide rights to the products and the most important markets are Germany, Spain, Switzerland, USA and France. Meda strengthens its position in key therapy areas; Cardiology, CNS and Pain / Inflammation.

The purchase price is 120 MEUR, corresponding to approximately 1 160 MSEK and equivalent to about 2,3 times sales. An up-front of 110 MEUR has been paid at closing of the transaction and the remaining 10 MEUR will be paid upon completion and assignment of certain agreements.

Activaero cooperates with Bayer in development of inhaled treatments

October 1, 2008

Under the terms of the agreement, Activaero will receive an upfront payment and in case the option will be exerted subsequently milestone payments as well.

Gene Network Sciences in collaboration with Biogen Idec

October 1, 2008

GNS will use its proprietary REFS software platform to process clinical data provided by Biogen Idec to identify targets and biomarkers in inflammation. A forward simulation model generated directly from the Biogen Idec data will be licensed to Biogen Idec at the conclusion of this project.

Financial terms of the agreement were not disclosed.

September 2008

Advinus and Ortho-McNeil-Janssen Pharmaceuticals in drug discovery and development collaboration

September 30, 2008

Advinus and OMJPI have agreed to develop drug candidates for various disease targets. Advinus will be responsible for drug discovery and early clinical development (until the completion of Phase 2a studies), while OMPJI will have an option to advance the drug candidates into late stage clinical trials and will be responsible for worldwide commercialization of the molecules.

As per the agreement, Advinus will receive an upfront payment and could receive milestone payments of up to US$ 247 million upon successful development of two targets. Advinus is also eligible for royalties on the sales of any drug products resulting from the collaboration.

MedImmune licenses reverse genetics technology to BIKEN

September 29, 2008

MedImmune will receive an upfront payment and has the potential to receive royalties on certain vaccine stockpiles or sales of other influenza products developed using the reverse genetics technology.

Indevus and Teva to develop pagoclone for the treatment of stuttering

September 26, 2008

Under the terms of the agreement, Indevus will conduct and Teva will reimburse Indevus for its expenses for a Phase IIb study. The placebo- controlled study will involve approximately 300 patients with stuttering in the U.S. treated for a period of six months and is expected to commence enrollment by Q1 2009.

Asterion and Genzyme in research alliance

September 25, 2008

Under the terms of the Agreement, Genzyme will gain access to elements of Asterion’s IP portfolio surrounding a specific protein target and will perform research work designed to look at the creation of a long-acting and potent version of an undisclosed protein of mutual commercial interest.

Merck and Japan Tobacco in osteoporosis deal

September 25, 2008

Merck gains worldwide rights, except for Japan, to develop and commercialize JTT-305. JT will receive an upfront payment and is eligible to receive additional cash payments upon achievement of certain milestones associated with the development and approval of a drug candidate covered by this agreement. JT will also be eligible to receive undisclosed royalties from sales of any drug candidates that receive marketing approval.

ChemBridge in discovery chemistry strategic alliance with AstraZeneca

September 25, 2008

This new alliance follows the previous collaboration between ChemBridge and AstraZeneca that was established in 2006 and successfully completed earlier this year ahead of schedule.

In accordance with the new agreement scientists from ChemBridge and AstraZeneca will work together to design and develop a new generation of highly advanced, research intensive small molecule libraries that further enhance AstraZeneca's global drug discovery effort. Further details and financial terms were not disclosed.

Roche completes acquisition of ARIUS Research

September 24, 2008

Roche has completed the acquisition of 100% of the issued and outstanding shares and warrants of ARIUS Research . On September 19th, the Ontario Superior Court, Canada, approved the Plan of Arrangement previously approved by the security holders and announced in a press release dated 23 July 2008. All other conditions of closing have been satisfied.

Teva and Kowa to partner in generic pharma company in Japan

September 24, 2008

New company to be named Teva-Kowa Pharma Co., which will seek to reach sales of $1 billion in 2015.

Maxygen in drug deal with Astellas Pharma

September 19, 2008

Under the agreement, the companies will co-develop MAXY-4 candidates for rheumatoid arthritis and other autoimmune diseases and Astellas will exclusively develop MAXY-4 candidates for transplant rejection. In addition, Maxygen has an option to co-promote any autoimmune therapeutic products developed under this alliance in North America. Regardless of indication, Astellas will manufacture the finished product using active drug substance provided by Maxygen and market and sell such product globally.

As consideration, Maxygen will receive a $10 million initial payment and is eligible to receive up to an additional $160 million in pre-launch milestone payments. Maxygen is also eligible to receive tiered double-digit royalties on all sales. If Maxygen exercises its option to co-promote, revenues from any such therapeutic product will be subject to a profit-sharing arrangement between the parties instead of royalty payment.

In addition to the $10 million up-front payment, Astellas will pay for the first $10 million of certain preclinical costs related to development of MAXY-4 candidates, after which the companies will share preclinical and development costs of MAXY-4 candidates for autoimmune disease indications in North America and European countries. Astellas will be responsible for development costs for autoimmune disease indications in the rest of the world and for transplant rejection indication worldwide.

Amsterdam Molecular Therapeutics obtains license to Amgen's GDNF gene to develop treatment for Parkinson's disease

September 18, 2008

License from Amgen to use their GDNF gene for the development of a gene therapy treatment for Parkinson's disease. The combination of this gene with AMT's proprietary adeno-associated virus (AAV) gene therapy platform could potentially allow the development of an effective, long-term treatment for this progressive and crippling disease.

Memory and Roche expand R3487/MEM 3454 development program

September 18, 2008

Under the terms of the amendment, Roche will provide funding to Memory Pharmaceuticals, in advance, for all costs associated with the increase in enrollment and will accelerate a portion of the $17.0 million payment associated with the completion of the Phase 2 CIAS trial as follows: $3.5 million in connection with entering into this amendment and $5.0 million upon the completion of enrollment for the CIAS trial. The payment of the remaining $8.5 million will become due 30 days following the availability of top-line data from the Phase 2 CIAS trial, which is now expected in the second quarter of 2009.

Merck ends research collaboration with SurModics

September 18, 2008

Merck’s decision triggers an additional $9 million payment to SurModics from Merck.

Merck’s decision to discontinue the collaboration was made following a strategic review of its business and product development portfolio.

Three Rivers Pharmaceuticals obtains additional commercial rights to Infergen from Amgen

September 16, 2008

Three Rivers Pharmaceuticals will obtain commercial rights to Infergen in all markets except Japan. In addition, Three Rivers Pharmaceuticals will obtain commercial rights to China effective March 31, 2009. Three Rivers Pharmaceuticals currently has commercial rights to Infergen in the United States and Canada.

Bayer HealthCare buys German biotech Direvo Biotech

September 16, 2008

DIREVO Biotech is acquired by Bayer HealthCare in an all cash deal at a transaction value of EUR 210 Million (approx. $300 Million). DIREVO Industrial Biotechnology GmbH, a wholly owned subsidiary of DIREVO Biotech AG, is not subject to this transaction and has been sold in a separate deal to a group of financial investors.

MannKind and Pfizer in collaboration for Exubera patients to transition inhaled insulin

September 16, 2008

MannKind will transition certain Exubera patients with a continuing need for inhaled insulin to MannKind’s inhaled insulin product, Technosphere Insulin.

WellDoc and AstraZeneca to develop asthma management solution

September 16, 2008

As part of its patient support program AstraZeneca’s respiratory franchise will utilize WellDoc’s web- and mobile-based asthma solution, including virtual messenger, air quality and pollen count alerts as well as online patient support tools, allowing patients to manage their condition, consistent with the treatment plan of the patient’s physician, throughout their day and in real time.

Biovitrum to acquire Kepivance and Stemgen and license Kineret from Amgen

September 15, 2008

The financial terms of the transaction include an upfront payment of approximately $130 million, consisting of $110 million in cash and ordinary shares of Biovitrum, representing a value of $20 million at the time of closing, subject to certain adjustments provided in the acquisition agreement.

In addition, the agreement provides for the payment of sales milestones and additional contingent payments under certain circumstances, including, without limitation, potential royalties in the event that Biovitrum develops modified forms of Kineret. Biovitrum will finance the cash portion of the transaction with debt and existing cash. The transaction is expected to close by the end of 2008.

MedImmune expands autoimmune disease research through collaboration with SBI Biotech

September 12, 2008

MedImmune is to provide SBI Biotech with an undisclosed upfront payment, milestone payments and royalties on future marketed products. SBI Biotech has granted MedImmune an exclusive license to research, develop and commercialize products that target the ILT7 protein. In addition, MedImmune will have the option to license additional targets resulting from SBI Biotech's research activities.

Pfizer Animal Health adds Schering-Plough products to european portfolio

September 11, 2008

Pfizer has acquired these assets for approximately euro 116 million in cash. The acquisition adds both biological and pharmaceutical products across the major animal health species including cattle, swine, equine and companion animal to Pfizer’s portfolio.

Accenture in 10-year agreement with BMS

September 10, 1008

Contract includes IT and financial support services. Accenture has signed a new 10-year, $550 million agreement with Bristol-Myers Squibb for a range of finance and accounting and application development and maintenance services.

GlaxoSmithKline and Cellzome in inflammatory diseases deal

September 10, 2008

Under the agreement GSK has exclusive options to license drug candidates from Cellzome's kinase programs directed against four identified targets, and three additional targets to be jointly identified by both parties.

In the alliance, Cellzome will utilize its proprietary Kinobeads technology to discover novel small molecule inhibitors of these targets, and then will develop the most promising product candidates through to completion of a clinical proof of concept trial, unless GSK elects to exercise its option earlier.

Cellzome is eligible to receive success-based milestones from GSK as product candidates are advanced. Upon Cellzome's achievement of clinical proof of concept for a product candidate for a particular kinase target, GSK would have an exclusive option to license all product candidates from that program.

GSK would then assume full responsibility for further clinical development and commercialization on a worldwide basis. Cellzome retains the right to continue the development and commercialization of drug candidates if GSK chooses not to exercise its option to that program.

Under the terms of the agreement, Cellzome will receive upfront payments of GBP14.4 million comprised of both cash and equity. Cellzome is eligible for up to GBP118 million per program in potential development, regulatory and commercial milestones and up to double digit royalties on net sales of products resulting from the alliance.

Bayer shares gain on talk of Pfizer interest

September 9, 2008

Shares in German drugs and chemicals group Bayer rose nearly 4 percent on Tuesday on market talk of takeover interest from Pfizer, traders said.

Orexo and Boehringer Ingelheim extend research collaboration

September 8, 2008

Extended their existing three year research collaboration for a further 12 months from November 2008. The research collaboration is a part of an exclusive world-wide license to develop and market a new class of drugs with a novel mechanism of action for the treatment of pain and inflammation.

Asterand to enter license deal with Allergan for pre-clinical compounds for eye disease

September 8, 2008

Allergan plans to further develop a focused list of Lead Compounds and progress these through Clinical Development.

Allergan will pay Asterand an upfront Technology Access Fee of $6.25 million. In addition, Asterand can receive success-based development and sales milestone payments that could total up to $56.0 million, plus royalties.

Second compound from AMRI - Bristol-Myers Squibb collaboration selected for preclinical development

September 8, 2008

AMRI will receive a $1.5 million milestone payment from Bristol-Myers Squibb Company for the nomination of this clinical candidate, marking the third milestone in the ongoing research collaboration between the two companies to develop improved treatments for depression and diseases of the central nervous system (CNS).

Under the 2005 licensing agreement, Bristol-Myers Squibb received an exclusive license to develop and commercialize a series of biogenic amine reuptake inhibitors from AMRI’s proprietary research program. The two companies will continue to evaluate additional compounds under this collaboration.

Cephalon ending Provigil promotion deal with Takeda

September 5, 2008

Cephalon has provided written notice to Takeda Pharmaceuticals North America that as of Nov. 1 Cephalon is ending its co-promotion agreement covering its sleep disorder drug Provigil.

Acucela and Otsuka enter co-development deal for ACU-4429 in dry age related macular degeneration

September 4, 2008

Otsuka shall pay Acucela a $5 million cash upfront payment, and potential milestone payments totaling $258 million. In addition, Otsuka will fund all clinical development activities through Phase II clinical testing. Beginning with Phase III clinical testing, the parties will share equally in all future clinical development expenses.

Otsuka will provide Acucela with a loan facility to enable it to fund its share of the development expenses through to launch of the product in North America.

Pfizer gains rights to Medivation Alzheimer's drug

September 3, 2008

Under the terms of the agreement, Medivation will receive an up-front cash payment of $225 million.

Medivation also is eligible to receive payments of up to $500 million upon the attainment of development and regulatory milestones plus additional undisclosed commercial milestone payments.

Medivation and Pfizer will collaborate on the Phase III program in Alzheimer’s disease, Huntington’s disease development and regulatory filings in the United States.

The companies will share all U.S. development and commercialization expenses along with U.S. profits/losses on a 60 percent/40 percent basis, with Pfizer assuming the larger share of both expenses and profit/losses.

In addition, Medivation will co-promote Dimebon to specialty physicians in the U.S.

Pfizer will have responsibility for development, regulatory and commercialization outside the U.S. and will pay Medivation tiered royalties on commercial sales outside of the U.S.

ZymoGenetics and Merck Serono change lupus deal

September 3, 2008

With respect to the ongoing development of atacicept, ZymoGenetics exercised its contractual right to convert to a worldwide royalty license.

By making this election, ZymoGenetics will no longer be responsible for funding development costs, and Merck Serono will fund 100% of the program costs on a worldwide basis. Merck Serono will now have exclusive worldwide development and commercialization rights for atacicept, including in North America.

Merck Serono will make milestone payments to ZymoGenetics, as agreed in the original contract between the two companies signed in 2001, and pay royalties on worldwide net sales.

GlaxoSmithKline scales back relationship with Adolor

September 3, 2008

GlaxoSmithKline has returned to Adolor the worldwide rights related to the development of the Entereg drug for chronic opioid bowel dysfunction.

Shionogi to acquire Sciele Pharma for $1.4 billion

September 2, 2008

Under the terms of agreement and pursuant to a tender offer, Shionogi will acquire all the outstanding shares of Sciele’s common stock at a price of $31 per share, for a total equity purchase price of approximately $1.1 billion.

Upon completion of the acquisition, Sciele will become a wholly-owned subsidiary of Shionogi and will continue operations in Atlanta, GA, USA as a standalone business unit. The Board of Directors of Shionogi and Sciele have approved this transaction.

August 2008

Shionogi to buy Sciele Pharma for $1.4 billion

August 29, 2008

Shionogi and Sciele Pharma announced a definitive agreement Monday under which the Japanese drugmaker will acquire Sciele for $1.4 billion. "Establishing additional overseas sales infrastructure has become an urgent priority for Shionogi in its pursuit of sustained growth in the mid- to long-term," the Osaka-based company stated.

The deal includes a $31-per-share tender offer, which represents a 61-percent premium over Sciele's closing price on August 29. Shionogi indicated that its tender offer will be launched within 10 days, and that the boards of both companies have approved the deal.

GlaxoSmithKline in deal with Valeant for adult epilepsy drug

August 28, 2008

Under the terms of the agreement, Valeant will grant GSK worldwide development and commercialization rights to retigabine, VRX698 and the other back-up compounds from the potassium channel opener discovery program in exchange for an upfront payment of $125 million to Valeant.

Additionally, GSK will pay Valeant up to $545 million based on the achievement of certain regulatory, development and commercialization milestones and the development of additional indications for retigabine.

Valeant will co-commercialize with GSK and will share up to 50 percent of net profits within the U.S., Canada, Australia, New Zealand and Puerto Rico, and will receive up to a 20 percent royalty on net sales of retigabine outside those regions. The two companies will jointly fund all global research and development expenses for retigabine, and GSK will completely fund the development of VRX698 and the other back-up compounds from the potassium channel opener discovery program.

Valeant could receive up to an additional $150 million based on the achievement of certain regulatory, development and commercial milestones for VRX698 and the back-up compounds and double-digit royalties on worldwide sales.

Biota Holdings RSV license assigned to AstraZeneca

August 25, 2008

The 2005 Collaboration and License Agreement with MedImmune has been assigned to AstraZeneca.

AstraZeneca has also secured the rights to a number of Asian and Pacific territories not held by MedImmune under the original agreement and for which Biota will receive an additional US$3.5 million payment, plus future royalties.

The Collaboration and License Agreement relates to a series of antivirals aimed at the treatment of respiratory syncytial virus. The assignment of the agreement results in part from AstraZeneca's acquisition of MedImmune in 2007.

Under the agreement, all existing milestone and royalty entitlements are preserved and Biota's research and development program has been extended. The lead candidate BTA9881 entered Phase I clinical trials in July 2007, which are continuing.

Genzyme and Medicines for Malaria Venture in new collaboration with Advinus Therapeutics to accelerate discovery of novel therapies for malaria

August 25, 2008

The collaboration seeks to develop new, improved treatments for specific patient groups most at risk for malaria, an often fatal infectious disease of developing countries, particularly affecting pregnant women and infants.

Noven signs license and supply agreements with Procter & Gamble Pharmaceuticals for patches to treat HSDD

August 21, 2008

Under the agreements, Noven granted P&GP an exclusive worldwide license to a testosterone patch for the treatment of HSDD in women, as well as potential next-generation patches in the same therapeutic category. The agreements provide for payment to Noven of royalties and manufacturing fees, as well as development and sales milestones, relating to the licensed products. P&GP will fund any clinical development costs and will be responsible for any regulatory filings and marketing applications associated with the licensed products, as applicable.

Boehringer Ingelheim extends research collarboration with Ablynx

August 21, 2008

In January 2007 Boehringer Ingelheim and Ablynx announced that they had entered into a $265 million worldwide research and licensing agreement to discover and develop new therapies for Alzheimer's disease using Ablynx's Nanobodies, a novel class of therapeutic proteins.

The deal also included a joint research programme with Ablynx scientists. Boehringer Ingelheim will be solely responsible for the development, manufacture and commercialization of any products resulting from the collaboration.

As part of the collaboration, Ablynx received an upfront fee and will receive development and commercial milestones as well as undisclosed royalties based on net sales.

BMS and PDL BioPharma in global alliance to develop multiple myeloma drug

August 20, 2008

Under the terms of the collaboration, Bristol-Myers Squibb would pay PDL BioPharma an upfront cash payment of $30 million for the development and marketing rights to elotuzumab and for an option to expand the collaboration to include PDL241, another anti-CS1 antibody, upon completion of pre-agreed preclinical studies.

PDL BioPharma could receive additional payments of up to $480 million based on pre-defined development and regulatory milestones and up to $200 million based on pre-defined sales-based milestones for elotuzumab in multiple myeloma and other potential oncology indications.

The companies will share development costs, with Bristol-Myers Squibb providing 80 percent of the funding and PDL BioPharma providing 20 percent. Bristol-Myers Squibb will lead global development activities, and PDL BioPharma will complete the ongoing Phase I program and provide support for Phase II studies.

The companies would share profits on sales of elozutumab in the U.S. PDL BioPharma would receive royalties on net sales of elotuzumab outside the USA.

If Bristol-Myers Squibb exercises its option to expand the collaboration to include PDL241, PDL BioPharma would receive an additional cash payment of $15 million and could receive additional payments of up to $230 million based on pre-defined development and regulatory milestones and up to $200 million based on pre-defined sales-based milestones. The same division of development costs and profit sharing that apply to elotuzumab would apply to PDL241.

CEL-SCI in exclusive licensing deal with Teva for cancer drug multikine

August 20, 2008

The licensing agreement is initially restricted to the areas of head and neck cancer. Teva has the right, subject to certain conditions, to extend the licensing agreement to include other cancers during the term of this agreement. Multikine is currently thought to be potentially useful in treating many tumor types.

Teva will participate in CEL-SCI's upcoming global Phase III clinical trial. Teva will fund a portion of the Phase III clinical study and Teva's clinical group will conduct part of the clinical study in Israel under the auspices of CEL-SCI and its Clinical Research Organization.

Teva will also be responsible for registering the product in the Territory. Once Multikine has been approved, CEL-SCI will be responsible for manufacturing the product, while Teva will be responsible for sales in the Territory. Revenues will be split 50/50 between CEL-SCI and Teva.

Lupin in marketing alliance with Forest for AeroChamber Plus brand in USA

August 20, 2008

Under the terms of the agreement, Lupin Pharmaceuticals, Inc., USA, will use its 50 person sales force to promote the product to pediatricians.

Eli Lilly completes SGX Pharmaceuticals acquisition

August 20, 2008

The deal, valued at a total purchase price of $64 million, will allow Lilly to integrate SGX's structure-guided drug discovery platform into its drug discovery efforts. It will also give Lilly access to FAST(TM), SGX's fragment-based, protein structure guided drug discovery technology, and to a portfolio of pre-clinical oncology compounds focused on a number of high-value kinase targets.

Eli Lilly acquires Posilac dairy business from Elanco

August 20, 2008

Under the terms of the agreement, Lilly will acquire all rights to the Posilac brand, as well as the product's U.S. sales force and its manufacturing facility in Augusta, Georgia. In return, Monsanto will receive a $300 million upfront payment, as well as contingent consideration. The Posilac dairy business manufacturing and sales teams will be integrated into the Elanco business.

Melior Discovery in research collaboration with AstraZeneca

August 19, 2008

Melior’s in-vivo theraTRACE indications discovery platform will be used to evaluate the therapeutic activity of selected AstraZeneca compounds.

Cellumen and Mitsubishi Tanabe collaborate in discovery toxicology

August 19, 2008

To develop panels of biomarkers that identify toxicity early in the drug development process.

Meda acquires world-wide rights to four products from Roche

August 15, 2008

The purchase price is 120 million Euro, equivalent to about 2 times sales. The acquisition is dependent on antitrust approval.

The four acquired Roche products are Marcoumar (phenprocoumon), Torem (torasemide), Tilcotil (tenoxicam) and Aurorix (moclobemide).

AstraZeneca announces partnership with Singapore institutions to develop anti-cancer compounds

August 15, 2008

The collaboration aims to further build AstraZeneca's drug development capabilities in Asia and ultimately speed up access to new medicines of potential benefit to patients with inoperable Hepatocellular Carcinoma (HCC).

Under the MOU, AstraZeneca and the Singapore institutions will be entering into a collaborative agreement that spans both clinical and pre-clinical development activities.

Cytos and Pfizer in Immunodrug vaccine technology deal

August 15, 2008

Cytos will receive upfront payment of 150 million Swiss francs ($138 million) and potential further milestones.

In return, the agreement will allow the U.S. drug maker to acquire world-wide exclusive rights to commercialize certain vaccines, based on Cytos Biotechnology's Immunodrug technology.

Karo Bio AB and Wyeth extend collaborations

August 14, 2008

Wyeth and Karo Bio have extended their atherosclerosis collaboration for an additional year until 31 August 2009.

Abbott and AstraZeneca expand relationship to include co-promotion of Crestor

August 14, 2008

Under the terms of the agreement, Abbott will obtain the non-exclusive right to promote CRESTOR alongside AstraZeneca in the United States, excluding Puerto Rico. Specific financial terms were not disclosed.

ImmunoGen announces Sanofi-Aventis licenses expanded access to TAP technology

August 13, 2008

The exercise of this option enables sanofi-aventis to evaluate, with certain restrictions, the Company’s maytansinoid TAP technology with antibodies to targets not included in the existing research collaboration between the companies and to license the exclusive right to use the technology to develop products to specific targets on the terms in the 2006 agreement.

ImmunoGen is entitled to earn upfront and milestone payments potentially totaling $32 million per target for each compound developed under the 2006 agreement, as well as royalties on commercial sales. ImmunoGen also is entitled to manufacturing payments for any materials made on behalf of sanofi-aventis.

Tekmira in RNAi research collaboration with Bristol-Myers Squibb

August 13, 2008

The relationship between Tekmira and Bristol-Myers Squibb builds upon earlier work conducted at Bristol-Myers Squibb using siRNA delivery technology provided by privately held Protiva Biotherapeutics Inc. In May, Protiva and Tekmira combined their businesses to create a leader in the field of RNAi (RNA interference) therapeutics.

Diakron licenses anticoagulant drug from Merck

August 13, 2008

Under the terms of the agreement, Diakron has the exclusive rights to develop, and, if approved, market and distribute the compound worldwide.

Bayer Schering Pharma buys Nycomed Pharma's preclinical oncology program

August 8, 2008

The agreement comprises two potential drug candidates and an extensive set of back-up compounds targeting a kinase critical for growth and survival of cancer cells. Bayer Schering Pharma will assume full development and commercialization rights of the program. The company is making this investment after Nycomed has taken the strategic decision to not further invest in oncology R&D activities.

Nycomed will receive an initial reward and payments upon completion of agreed preclinical and regulatory milestones. Overall compensations could total at 52 million Euro.

Metabasis in collaboration with Roche to develop liver-targeted compounds for hepatitis C

August 8, 2008

Under the terms of the agreement, Roche will provide a $10 million upfront payment. In the event a development candidate is identified, Roche will assume development responsibility, and Metabasis will be eligible to receive up to $193 million in additional payments upon achievement of predetermined preclinical and clinical development events, as well as regulatory and commercialization events for each product.

For any marketed products that result from the collaboration, Roche will retain full commercial rights and pay Metabasis a royalty on net sales.

Sonus in exclusive licensing deal with Bayer for caspase activator compounds

August 7, 2008

Under terms of the agreement, Sonus was granted exclusive rights to develop two core compounds for all prophylactic and therapeutic uses in humans. Additionally, Sonus was granted rights to all other non-core compounds covered under the patents for use in oncology. Bayer retained rights to develop biological conjugates of the molecules (excluding the two core compounds), and agreed not to develop the non-core compounds as small molecules or pro-drugs for use in oncology.

Under the terms of the agreement, Bayer will receive an upfront license fee of $450,000, milestone payments, and royalties on sales of any compounds successfully commercialized upon FDA approval. Specific financial terms on milestone payments and royalties were not disclosed. The upfront license fee and anticipated costs for advancing the compound to Phase 1 clinical development were included in prior financial forecasts provided by Sonus.

Ore Pharmaceuticals acquires rights to develop a second drug candidate from Roche

August 7, 2008

Ore Pharmaceuticals files for patents, plans to develop and out-license candidate for metabolic conditions such as obesity or high cholesterol.

Ore Pharmaceuticals acquired the development rights for romazarit through its partnership with Roche, where it was initially developed as an anti-inflammatory compound and had reached Phase II clinical testing for rheumatoid arthritis. Repositioning efforts at Ore Pharmaceuticals discovered that romazarit modulates a key pathway related to metabolic function.

Covance and Eli Lilly execute 10 year services contract

August 6, 2008

Under the agreement, Covance will acquire Lilly's 450-acre early drug development campus in Greenfield, Indiana for $50 million and will offer employment to about 260 Lilly employees. In addition, Covance will provide Lilly with a broad-range of drug development services over the next ten years for a contract value of $1.6 billion. Under the agreement, Covance will assume ownership of the site and operations on or about October 1, 2008.

Under this agreement Lilly will transfer responsibility to Covance for its non-GLP toxicology, in vivo pharmacology, quality control laboratory, and imaging services. In addition, the contract includes a committed level of clinical pharmacology, central laboratory, GLP toxicology studies, and clinical Phase II-IV services.

Phase Forward and Eli Lilly extend multi-year agreement

August 6, 2008

Since 2001, Lilly has utilized Phase Forward’s InForm product in over 200 trials and plans to continue to use InForm for global trials across all phases, as well as mandating the use of the InForm product with its global service partners.

Capricorn Pharma and TEVA Pharmaceuticals USA enter agreement

August 5, 2008

Agreement with Teva Pharmaceuticals USA to develop products using Capricorn’s proprietary KORKOAT technology platform. Terms of the agreement were not disclosed.

Regeneron in VelociGene deal with Sanofi-Aventis

August 5, 2008

Sanofi-aventis will pay Regeneron a minimum of $4.3 million annually for five years for knock-out and transgenic models of gene function for target genes identified by sanofi-aventis. Sanofi-aventis will use these models for its internal research programs, outside the scope of its antibody collaboration with Regeneron.

Gilead and Merck in agreement to register and distribute HIV medication Atripla in twelve countries

August 1, 2008

Under the terms of the agreement, Gilead will assume the lead role in the registration, manufacturing and distribution of Atripla in Argentina, Australia, Chile, Hong Kong, Israel, Mexico, New Zealand, Russia, Taiwan, Thailand, Turkey and Uruguay.

The companies will make Atripla available in the 12 countries covered by this agreement as rapidly as feasible, and will share the revenues and costs associated with registering and distributing the product. Going forward, additional countries may be added to this new agreement by mutual consent.

Amgen licenses molecule for treatment of chronic and neuropathic pain to Ortho-McNeil-Janssen

August 1, 2008

The terms of the agreement include a $50 million upfront payment, the potential for $385 million in success-based milestones and additional sales based milestones and royalties on sales.

The agreement provides OMJPI with global rights to the product, but excludes Japan where Amgen has entered into a previous license agreement with respect to the compound. OMJPI and its affiliates will be responsible for future development and commercialization of the compound, a fully human anti-nerve growth factor (NGF) antibody.

July 2008

Bristol-Myers Squibb offers to buy ImClone Systems for $60 a share

July 31, 2008

Total payment of approximately $4.5 billion, to equity holders of ImClone, other than Bristol-Myers Squibb. Bristol-Myers Squibb currently owns approximately 17 percent of all outstanding shares of ImClone.

MitoScience and Roche collaborate to investigate mitochondrial toxicity

July 31, 2008

Under the agreement Roche will provide the compound library plus previously-gathered data from in vivo and in vitro experiments, and MitoSciences will apply its MitoTox technology to provide in vitro data for a broad set of mitochondrial toxicity endpoints.

Javelin and Baxter expand commercial supply relationship for anticipated Dyloject global growth

July 31, 2008

The expanded relationship provides additional manufacturing capacity for Dyloject, principally for distribution in the European Union, and builds on the existing manufacturing agreement executed between Javelin and Baxter for the United States.

Mylan acquires remaining interest in Somerset Pharmaceuticals joint venture from Watson

July 29, 2008

Mylan and Watson announced that Mylan has acquired Watson's 50 percent interest in the Somerset Pharmaceuticals joint venture.

Zhejiang Huahai in deal to provide finished drug product to Merck

July 29, 2008

Zhejiang Huahai Pharmaceutical has signed an agreement with Merck to provide an unnamed finished product to the big pharma.

The deal represents a move up for Huahai Pharma, which has traditionally provided APIs to western pharmaceutical companies, as well as finished drugs in China.

Under the agreement, Huahai Pharma will formulate, produce and package the drug. Merck will distribute the product worldwide.

Simulations Plus and Roche sign multi-year collaboration

July 28, 2008

A multi-year collaboration agreement with Roche that will provide funding for the equivalent of one full-time scientist for two years to expand the capabilities of its flagship GastroPlus software program. The agreement includes close collaboration with Roche scientists to advance the capabilities of GastroPlus in the area of simulating drug-drug interactions.

NovaMed and Sanofi-Aventis extend collaboration in China

June 28, 2008

The ongoing collaborative relationship between the two companies began in 2006 with Xatral, the first product in a class of alpha1-blockers to treat benign prostatic hyperplasia (BPH). A recent IMS Health report revealed that Xatral has demonstrated very strong growth, notably at the highest rate in the BPH treatment market since the cooperation with NovaMed began. The focus on collaboration with multinational pharmaceutical companies in China underscores the opportunity for NovaMed to expand hospital coverage in various cities across China and facilitate greater patient access to clinically proven and effective therapies.

Sanofi-Aventis to buy Acambis for $548 Million

July 25, 2008

Sanofi Pasteur, a vaccines division of Sanofi-Aventis, will buy Acambis for a total of about 276 million pounds ($549.5 million) or 190 pence a share. The offer price is a 65% premium to Acambis' share price of 115 pence at the close of business on July 24.

Dynavax in flu vaccine deal with Novartis

July 24, 2008

Novartis will give Dynavax trivalent influenza vaccine to be used as a component of the universal vaccine, in exchange for an exclusive option to negotiate a development and marketing deal with Dynavax.

Pharmacopeia advances therapeutic program with GlaxoSmithKline

July 24, 2008

This newly identified lead is the first from a program being evaluated as a potential treatment for pain and the fifth lead identified since the alliance was initiated in 2006. As a result of this success, Pharmacopeia will receive a $500,000 milestone payment from GSK.

Pharmacopeia is entitled to success-based milestone payments totaling up to $83 million per program and potentially double-digit royalties on the sales of any product commercialized by GSK under the multi-program alliance. Should GSK decline its option to complete pivotal trials of alliance programs, Pharmacopeia would maintain future development and commercialization rights.

Innovative investment relationship to develop Eli Lilly's two lead Alzheimer's molecules

July 24, 2008

The arrangement calls for NovaQuest and TPG-Axon Capital, NovaQuest’s primary investment partner on co-development and co-promotion deals, to provide >$300 million to help Lilly fund the aggressive development of the molecules – a gamma-secretase inhibitor and an A-beta antibody.

In exchange for their funding, TPG-Axon Capital and NovaQuest will receive success-based milestones and royalties contingent on the successful development of the Alzheimer’s molecules.

GlaxoSmithKline in $25 million-plus deal with Harvard Stem Cell Institute

July 24, 2008

GlaxoSmithKline has signed a five year $25 million-plus deal with the Harvard Stem Cell Institute to harness stem cell technology for the development of new medicines.

Roche to buy ARIUS Research

July 23, 2008

The two companies have signed a definitive agreement for Roche to acquire ARIUS in an all-cash transaction at a price of approximately C$191 million.

Roche will pay C$2.44 for each common share of ARIUS Research Inc. This price represents a 15% premium to the closing price on 22 July 2008 and a 44% premium to the 20-day volume-weighted average closing price ending 15 May 2008 (the last trading day prior to ARIUS' announcement that third parties have shown interest in the company and its technologies). Roche will also acquire all of the issued and outstanding warrants of ARIUS. Roche will pay C$1.44 for each Class F Warrant and C$1.78 for each Class G Warrant.

MorphoSys licenses RapMAT technology to Astellas

July 23, 2008

Astellas will have access to MorphoSys's RapMAT technology module alongside the existing installation of the Company's proprietary antibody library HuCAL GOLD at Astellas' research site in Tsukuba, Japan. Under the extended agreement MorphoSys will receive annual user fees for the RapMAT technology and continues to receive annual user fees for access to its HuCAL platform.

Teva completes acquisition of Bentley Pharmaceuticals

July 23, 2008

Teva has completed its acquisition of Bentley Pharmaceuticals, which will operate in Spain under the Teva name. At closing, Bentley consisted solely of its generic pharmaceutical operations, following the spin-off of its drug delivery business to its stockholders on June 30, 2008. The aggregate purchase price paid by Teva was approximately $360 million in cash, or approximately $14.82 per Bentley share.

Roche acquires Mirus Bio Corporation

July 22, 2008

Under the terms of the agreement, Roche will fully acquire Mirus for USD 125 million and will maintain an RNAi research site in Madison. Mirus' transfection reagents business will be divested into a standalone business to be known as Mirus Bio LLC, without any anticipated effect on existing customers. Employees will be offered a transition into their respective business unit. Closing of the transaction is subject to standard conditions. Completion is expected during the second half of 2008.

Roche offers to buy out Genentech for $43.7 Billion

July 21, 2008

Roche has proposed to acquire the outstanding publicly held interest in Genentech for US$89.00 per share in cash, or a total payment of approximately US$43.7 billion to equity holders of Genentech other than Roche.

Roche acquired a majority in Genentech in 1990 and currently owns 55.9% of all outstanding shares.

Sanofi-Aventis to acquire Symbion

July, 21 2008

Sanofi-Aventis to acquire Symbion from Primary Health Care for $545 million.

Gamida Cell in license deal with Amgen to support development and commercialization of StemEx

July 21, 2008

Under the terms of the agreement, Amgen will receive a minority equity interest in Gamida Cell in addition to royalty payments from future sales of StemEx for hematological diseases. Gamida Cell will receive a non-exclusive license to manufacture and utilize a number of cytokines for StemEx manufacturing.

Teva Pharmaceutical to buy Barr Pharmaceuticals for $7.46 Billion

July 18, 2008

Under the terms of the agreement, each share of Barr common stock will be converted into $39.90 in cash and 0.6272 Teva ADRs. Based upon the unaffected NASDAQ closing price of Teva’s ADRs on July 16, 2008, the indicated combined per share consideration for each outstanding share of Barr common stock amounts to $66.50, or a total consideration of $7.46 billion plus the assumption of net debt of approximately $1.5 billion.

Boehringer Ingelheim licenses drug targets from autoimmune collaboration with Galapagos

July 17, 2008

This is the second milestone reached in the three-year collaboration initially announced in January 2006. In the collaboration, BioFocus DPI applied its SilenceSelect shRNA-based gene collection to run a target discovery screen for Boehringer Ingelheim's autoimmune discovery research.

BioFocus DPI obtained upfront fees, research and development funding and will receive milestone fees when certain drug discovery criteria are met. Should all criteria on a target be achieved, total potential contract value for BioFocus DPI may exceed EUR 2 million per target.

Genzyme and PTC Therapeutics in collaboration on small molecule for genetic diseases

July 17, 2008

Under the terms of the agreement, PTC will commercialize PTC124 in the United States and Canada, and Genzyme will commercialize the treatment in all other countries. Genzyme will make an up-front payment of $100 million to PTC, plus potential milestone and royalty payments. PTC will be financially responsible for one ongoing and three additional clinical trials of PTC124, which is potentially applicable to hundreds of genetic diseases.

Alnylam announces extension of RNAi collaboration with Novartis

July 16, 2008

Novartis has elected to extend the company’s RNAi therapeutics collaboration for an additional year, through October 2009. The landmark alliance was initiated in October 2005 and is focused on the discovery, development, and commercialization of RNAi therapeutics toward a defined number of Novartis-selected disease gene targets.

Wyeth Consumer Healthcare in agreement to purchase ThermaCare from Procter & Gamble

July 15, 2008

ThermaCare fits Wyeth Consumer Healthcare's strategy to accelerate growth through innovation, organic geographic growth and strategic acquisitions in the division's base business, which includes some of the world's best-selling pain management, respiratory, nutritional, gastrointestinal and topical products. ThermaCare will join the company's pain franchise that includes Advil -- one of the world's leading oral pain relievers -- and will enhance Wyeth's global position in pain management.

West's MixJect system selected by Watson for use in treatment of prostate cancer

July 15, 2008

Watson has selected MixJect as the new delivery system for TRELSTAR (triptorelin pamoate for injectable suspension), a palliative treatment for advanced prostate cancer. The MixJect system, developed and manufactured by West’s subsidiary Medimop Medical Projects Ltd.

GlaxoSmithKline to pay Actelion up to $3.3 billion for drug rights

July 14, 2008

GlaxoSmithKline announced a deal to pay as much as $3 billion to Switzerland's Actelion to license a sleep-disorder drug in yet another example of a major drug firm turning to a smaller rival to build out pipelines.

Terms call for GSK to pay Actelion 150 million Swiss francs ($147 million) up front, with additional payments of as much as 415 million francs should the drug, called almorexant, be successfully developed to treat insomnia.

If regulators approve three uses for almorexant and if "exceptional" sales targets are met, Actelion could receive as much as 2.74 billion francs. Actelion will continue to lead the development program, with Glaxo paying 40% of the costs.

QLT Ccompletes divestment of Aczone to Allergan

July 14, 2008

The Aczone asset purchase agreement is the second agreement entered into by the Company to divest non-core assets since it announced its strategic restructuring earlier this year. Other assets offered for sale from QLT USA include Eligard and the Atrigel drug delivery system. In addition, on May 15, QLT announced that it had signed a sale and purchase agreement to sell the land and building comprising its corporate headquarters and an adjacent undeveloped parcel of land in Vancouver, British Columbia. Provided the closing conditions are removed within the time period provided under the sale and purchase agreement, the transaction is expected to close by mid-August.

Immunomedics in license deal with Nycomed

July 14, 2008

Agreement provides Nycomed with a worldwide license to develop, manufacture and commercialize veltuzumab, Immunomedics' humanized anti-CD20 antibody in the subcutaneous formulation for the treatment of all non-cancer indications.

Immunomedics will receive a non refundable initial cash payment of $40 million, subject to applicable Hart-Scott-Rodino Act approval, and could receive potential cash milestone payments of up to $580 million upon completion of certain clinical, regulatory, and sales-based milestones, as well as escalating double-digit royalties on sales of veltuzumab.

Novartis to acquire Speedel Holding AG

July 10, 2008

A binding agreement with Novartis under which Novartis purchased all their registered shares of the company for a total consideration of CHF 525.4 million. This represents a purchase price of CHF 130.00 per registered share.

Altus in long-term supply deal With Novartis for growth hormone

July 10, 2008

Under the deal, Novartis' Sandoz GmbH will continue supplying human growth hormone for Altus' ALTU-238 program. The drug candidate is a long-acting human growth hormone, which is aimed at being administered through injections just below the skin. Sandoz GmbH has already been supplying the component throughout the ALTU-238 program.

Eli Lilly pays Entelos for perpetual license

July 10, 2008*

Eli Lilly exercised its right to a perpetual license to Entelos' DrugMatrix database and additional customized report services. Lilly will make a one-time payment to Entelos for a perpetual license and has the option for continued support.

Eli Lilly to acquire SGX Pharmaceuticals

July 9, 2008

Under the terms of the agreement, Lilly will acquire all of the outstanding shares of SGX common stock at a price of $3.00 per share, for a total purchase price of approximately $64.0 million.

The acquisition will allow Lilly to integrate SGX's structure-guided drug discovery platform into its drug discovery efforts. It will also give Lilly access to FAST, SGX's fragment-based, protein structure guided drug discovery technology, and to a portfolio of pre-clinical oncology compounds focused on a number of high-value kinase targets.

Seattle Genetics in antibody-drug conjugate collaboration with Daiichi Sankyo

July 8, 2008

Under the terms of the collaboration, Seattle Genetics will receive an upfront payment of $4 million, progress-dependent milestone payments and mid-single digit royalties on worldwide net sales of resulting ADC products. Daiichi Sankyo is responsible for research, product development, manufacturing and commercialization of all ADC products under the collaboration. Seattle Genetics will receive material supply and annual maintenance fees as well as research support payments for assistance provided to Daiichi Sankyo in developing ADC products.

Paladin Labs and Procter & Gamble Pharmaceuticals in Canadian co-promotion agreement for Seasonale

July 3, 2008

Under the co-promotion agreement, Paladin will maintain regulatory and supply responsibilities for SEASONALE and will continue to support SEASONALE using its national specialty sales force. P&G Pharmaceuticals Canada will provide marketing, promotion, trade distribution and will deploy a national sales force in support of SEASONALE.

ARYx Therapeutics announces Procter & Gamble exercises option to end collaboration on ATI-7505

July 3, 2008

Under the terms of the collaboration agreement between P&G and ARYx Therapeutics, the results from the just-completed TQT study qualified ARYx for the Tier 1, or highest, milestone payment from P&G. The collaboration agreement provides P&G a thirty-day option period from the lock of the database for the TQT study to cancel the collaboration or agree to pay ARYx the milestone payment provided for under our collaboration agreement. P&G has exercised their option to cancel the agreement effective immediately. However, P&G has also been very supportive in agreeing to a transition plan for handing the program back to ARYx to allow it to pursue an optimal partnering package.

As part of the transition plan, the on-going Phase 2 studies in chronic constipation and functional dyspepsia will be terminated in an orderly method. No new patients will be enrolled and those currently on therapy will be withdrawn from the studies over the coming weeks. This will allow ARYx to continue to focus its resources on the on-going trials on ATI-5923 and ATI-2042.

Innogenetics grants cervical cancer licence to GlaxoSmithKline

July 2, 2008

A worldwide, non-exclusive license to use its SPF10 primer technology in cervical cancer vaccine studies.

Innogenetics to receive royalties for each test performed during the studies.

Bayer and Maxygen in hematology deal

July 2, 2008

Acquisition of Maxygen’s hemophilia program assets, including a next-generation recombinant Factor VIIa protein known as MAXY-VII.

The lead therapeutic candidate is expected to enter Phase 1 clinical testing in the third quarter of 2008.

The total transaction is valued at $90 million upfront with a final, potential milestone payment of $30 million. This agreement includes a license to use Maxygen’s MolecularBreeding technology, a novel research platform, for exploiting gene targets.

Schering-Plough completes divestiture of selected animal health products

July 2, 2008

These divestments were requested by the European Commission as part of its October 2007 clearance of the acquisition of Organon BioSciences N.V.

In Europe, Virbac acquired products from the endocrine, mastitis and sulphonamide franchises of Intervet/Schering-Plough Animal Health. The agreement does not affect the marketing of these products in other global markets. In a second agreement with Virbac that has also closed successfully, Virbac acquired Prosolvin, a product from the fertility range, for worldwide use. That acquisition also satisfied a request by the South African Competition Commission in connection with Schering-Plough's 2007 acquisition of Organon BioSciences N.V. Virbac has acquired these assets for an aggregate euro 28 million in cash.

By separate agreement announced in April, products from Intervet/Schering-Plough Animal Health's parasiticide, swine E. coli vaccine, ruminant clostridia vaccine, equine influenza vaccine, ruminant neonatal vaccine, anti-inflammatory, companion animal/insulin and companion animal/euthanasia, and rabies vaccine franchises will be acquired by a subsidiary of Pfizer. The closing of that transaction is expected to take place later this year following receipt of necessary regulatory approvals.

Cubist to promote AstraZeneca's broad spectrum antibiotic MERREM in USA

July 2, 2008

Cubist will promote and support MERREM I.V. using its existing U.S. acute care sales and medical affairs organizations. AstraZeneca will continue to provide marketing and commercial support for MERREM I.V.

The agreement, effective July 1, 2008, establishes a baseline of $20 million annual revenue to Cubist that will be adjusted based on actual MERREM I.V. sales.

Bioniche acquires Baxter's ENLON and ENLON-PLUS

July 2, 2008

Bioniche purchased the rights and certain assets related to the ENLON product line from Baxter, which discontinued ENLON in February 2008.

Bioniche anticipates launching all three codes of ENLON in October 2008.

Palatin amendment expands AstraZeneca obesity collaboration

July 1, 2008

Under the amendment, Palatin has agreed to license additional compounds and associated intellectual property to AstraZeneca. Palatin will receive development and regulatory milestone payments if any additional compound advances into human clinical trials, and sales target milestone payments and stepped royalties if any additional compound is commercialized.

June 2008

NovaMed to market six cancer drugs in China for Pfizer

June 30, 2008

NovaMed will sell and promote six anti-tumor drugs in China for Pfizer China, a subsidiary of big pharma company Pfizer Inc. The contract began in June 2008.

GlaxoSmithKline sells four drugs to Aspen Pharmacare

June 30, 2008

The medicines involved are Eltroxin, a thyroid hormone for hyperthyroidism; Lanoxin, a cardiac glycoside for heart failure; Imuran, an immunosuppressant; and Zyloric, an enzyme inhibitor for the treatment of gout.

Aspen will own the four drugs in all major markets outside of the United States, except for rights to Zyloric in Japan.

Bristol-Myers Squibb completes acquisition of KOSAN Biosciences

June 27, 2008

As a result of the transaction, Kosan has become a wholly-owned subsidiary of Bristol-Myers Squibb.

Bristol-Myers Squibb initiated a cash tender offer on May 29, 2008 to purchase all outstanding common stock of Kosan for $5.50 per share. The tender offer expired at midnight EDT on June 25, 2008, at which time approximately 41,449,606 shares, including 1,682,151 shares subject to guaranteed delivery procedures, were tendered, representing approximately 97.1% of the shares outstanding. Today Bristol-Myers Squibb acquired all of the remaining outstanding shares of Kosan. These shares, other than those owned by stockholders of Kosan who properly perfect their appraisal rights under Delaware law, were converted into the right to receive $5.50 per share, in cash and without interest, less any required withholding taxes.

Melior Discovery signs option agreement with Pfizer

June 25, 2008

Option agreement provides Pfizer the exclusive right to negotiate a license to MLR-1023, Melior’s drug candidate for Type II diabetes.

In exchange, Pfizer agreed to make an undisclosed payment to Melior and provide access to certain data it owns related to MLR-1023. In addition, Melior agreed to utilize its in-vivo theraTRACE indications discovery platform to evaluate the activity of selected Pfizer compounds in partnership with Pfizer.

Barr and Bayer sign supply and licensing agreements for launch of generic Yasmin and Yaz oral contraceptives

June 24, 2008

Under terms of these agreements, Bayer will supply Barr with the generic products for launch prior to the expiration of the patents protecting these products and Barr will have sole responsibility to market, sell and distribute the products in the U.S. under the Barr Laboratories label.

Boehringer Ingelheim and GENEART collaborate on offering design and production services for DNA therapeutics and vaccines

June 24, 2008

The collaboration includes a transfer of Boehringer Ingelheim technology to GENEART for the production and purification of plasmid DNA. The two partner companies also plan to closely collaborate in the distribution and marketing of their complementary services.

The collaboration offers a unique system solution for the development of DNA-based pharmaceuticals. GENEART will use the Boehringer Ingelheim production and purification technology to deliver DNA-based agents for research, development and preclinical studies. Boehringer Ingelheim will produce the pharmaceuticals under cGMP (current Good Manufacturing Practice) conditions for the subsequent clinical phases and the market.

Genzyme and Isis complete licensing of Mipomersen

June 24, 2008

The collaboration provides Genzyme with exclusive worldwide rights to mipomersen, a novel lipid-lowering drug discovered and developed by Isis that is in phase 3 clinical development. During the second half of this year, enrollment is expected to be completed in a pivotal study of mipomersen in homozygous familial hypercholesterolemia, and a new trial in apheresis-eligible patients is expected to begin.

As part of the agreement, Isis will receive a $175 million license fee for mipomersen. In February, Isis received a $150 million payment from Genzyme to purchase 5 million shares of Isis common stock at $30 per share.

The companies have updated the deal terms so that Isis will contribute up to $50 million in additional development funding for mipomersen, bringing Isis' development funding commitment up to $125 million. Thereafter Isis and Genzyme will share development costs equally. The initial Isis development funding commitment and the shared funding will end when the program is profitable. In exchange for this additional contribution, Isis has the opportunity to receive $75 million in milestone payments early.

Scil Proteins in manufacturing deal for Reteplase with Roche

June 24, 2008

Under the terms of the deal, Roche will transfer technology and know-how for the production of recombinant plasminogen activator (rPA) to Scil Proteins Production GmbH. rPA is the active ingredient of Rapilysin for the treatment of acute myocardial infarction which is marketed by Actavis.

Emisphere in license agreement with Novo Nordisk to develop oral formulation of GLP-1 receptor agonists for diabetes

June 23, 2008

The agreement includes at least $87 million in product development and sales milestone payments to Emisphere, of which $10 million will be the minimum first year payment, as well as royalties on sales. The agreement also provides Novo Nordisk with the option to develop oral formulations of Novo Nordisk compounds other than GLP-1 receptor agonists using Emisphere's proprietary carrier technology. Further financial details of the agreement were not made public.

Under the new agreement, Novo Nordisk is responsible for the development and commercialization of the product candidates. Novo Nordisk and Emisphere have collaborated since 2007 on early-stage pre-clinical research that has preliminarily confirmed the utility of Emisphere's carriers to provide bioavailable oral formulations of GLP-1 receptor agonists.

FDA licenses Sanofi Pasteur new pediatric combination vaccine, Pentacel

June 23, 2008

The FDA licensure of Pentacel vaccine is based on the results of multi-center clinical studies conducted in the U.S. and Canada involving more than 5,000 children who received at least one dose of Pentacel vaccine.

EyeCyte secures series A funding from Pfizer

June 23, 2008

The financing will fund the company into 2010 and will be primarily used to drive product development of the company’s initial clinical target, diabetic retinopathy.

Under the terms of the deal, Pfizer has invested $3 million in Series A Preferred shares of EyeCyte. Pfizer will be the sole pharmaceutical partner and will have an Advisory and Board role, helping to facilitate technology applications that will have meaningful pharmaceutical and patient impact. Pfizer will also have right of first refusal for a buy-out of EyeCyte or its technologies.

Cytokinetics in third extension of research term under collaboration with GlaxoSmithKline

June 20, 2008

The strategic alliance, initiated in June 2001, included an initial five-year research term and has been extended on two prior occasions, in each case with the objective to conduct joint research directed towards CENP-E. The companies have agreed again to extend the research program for an additional year, during which each company, at its own expense, will continue to perform translational research directed towards CENP-E in accordance with an agreed plan.

GlaxoSmithKline collaborates with National Cancer Institute to make large body of cancer cell genomic data available to all cancer researchers

June 20 ,2008

GlaxoSmithKline announced today the release of genomic profiling data for over 300 cancer cell lines via the National Cancer Institute's cancer Bioinformatics Grid (caBIG). The caBIG initiative is a network of infrastructure and tools that enables the collection, analysis, and sharing of data and knowledge along the entire research pathway from laboratory bench to patient bedside. By releasing the cell line data via caBIG, GSK could be enabling other cancer research institutions to save considerable drug development time and capital in their future cancer therapeutic research.

Trubion Pharmaceuticals announces extension of research period under its Wyeth collaboration

June 20, 2008

Wyeth has exercised its option under the terms of its collaboration agreement with Trubion to extend the research period for an additional one-year period through Dec. 22, 2009.

Under the terms of the research period extension, Wyeth's obligations to Trubion include collaboration research funding commitments of approximately $3.2 million in exchange for committed research services through Dec. 22, 2009.

Alnylam Pharmaceuticals ties up with Kyowa Hakko on respiratory drug in Asia

June 19, 2008

Under the terms of the collaboration, Kyowa Hakko will pay Alnylam $15 million in an upfront cash payment and up to an additional $78 million in development and sales milestone payments. Upon commercialization, Alnylam will receive double-digit royalties from Kyowa Hakko based on the sales of ALN-RSV01 in this territory.

The partnership also includes additional RSV-specific RNAi therapeutic compounds that comprise the ALN-RSV program. Alnylam retains all development and commercialization rights worldwide excluding Asia.

Oculus Innovative Sciences in agreement with Bayer Australia Limited for development of Microcyn technology use in Australian animal market

June 19, 2008

As part of the agreement, Bayer will be responsible for securing Australian regulatory approvals for the use of Microcyn Technology in the Australian companion animal and food animal markets.

Upon receipt of the regulatory approvals, Bayer retains right of first negotiation to enter into a distribution agreement for Oculus’ Vetericyn animal brand (formulated with the Microcyn Technology) in Australia.

Merck Serono and Bionomics in multiple sclerosis development and licensing agreement

June 18, 2008

Under the agreement, Bionomics will receive an upfront payment of US$ 2 million and committed research funding. Merck Serono will fund all development activities, including clinical development. Merck Serono intends to select compounds from Bionomics pool of compounds, and for each compound selected Bionomics may receive milestone payments of up to US$ 47 million, based on successful development and commercialization. In addition, Bionomics will be eligible to receive undisclosed royalties on the net sales of licensed products.

Roche signs cancer alliance with BioInvent and ThromboGenics

June 18, 2008

Under the terms of the agreement effective from June 17, 2008 (or if a U.S. anti-trust clearance is required, from the date of receipt of such clearance), Roche will pay BioInvent and ThromboGenics an upfront payment of €50 million. In addition, BioInvent and ThromboGenics could potentially receive up to €450 million over the term of the collaboration based on the successful completion of a series of development and commercial milestones for multiple indications, as well as double digit royalties on potential product sales, including any backup antibodies based on inhibition of PlGF. ThromboGenics, which discovered TB-403, will receive 60% and BioInvent 40% of the revenue from the deal. Roche will have a worldwide, exclusive license to develop and commercialize TB-403. BioInvent and ThromboGenics will retain co-promotion rights for the product in the Nordic, Baltic and Benelux regions.

BioInvent and ThromboGenics are responsible for any remaining costs associated with the recently completed Phase Ia trial in healthy volunteers. Roche will assume responsibility for all future development costs for this novel therapy, including the costs of the pending Phase Ib trial in patients to be run by BioInvent and ThromboGenics. BioInvent and ThromboGenics in conjunction with Roche will form a Joint Steering Committee to oversee research and development activities. In addition, Roche will also provide funding to BioInvent and ThromboGenics for research on non-cancer indications and supply of clinical material until transfer of manufacturing.

Monogram Biosciences collaborates with Gilead for Elvitegravir

June 18, 2008

Agreement with Gilead Sciences to provide resistance testing and consultative services for Gilead's Elvitegravir Phase III studies. Monogram assays will be used to screen patients for study enrollment and help select drugs to be given in conjunction with Elvitegravir during the study. Both Monogram's Integrase phenotype and genotype assays were used in Elvitegravir preclinical and Phase II studies, and will be used to evaluate Phase III patient outcomes. The Phase III studies are anticipated to begin enrolling patients later this year.

Cell Therapeutics in agreement with Bayer Schering for access to Zevalin FIT trial data

June 18, 2008

Based on these data the European Medicines Commission recently approved Zevalin for use as consolidation therapy after remission induction in previously untreated patients with follicular lymphoma. The benefit of Zevalin following rituximab in combination with chemotherapy has not been established.

Nuevolution in research and development collaboration with Merck & Co

June 18, 2008

Nuevolution will apply its proprietary Chemetics® drug discovery technology to identify novel small molecule leads against several drug targets of interest to Merck. The Chemetics platform uses innovative DNA labeling to allow fragment-based drug screening at an unprecedented scale.

Nuevolution will screen multiple multi-million member diverse fragment based screening libraries for hit identification. Through the design, synthesis and screening of target focused Chemetics follow-up libraries, the parties will also work together to perform hit-to-lead optimization.

Under the terms of the agreement, Merck will provide Nuevolution with an upfront payment, research funding, and milestone payments as candidate molecules progress through preclinical and clinical development and onto the market. In addition, Nuevolution is eligible to receive royalties on the commercial sales of approved products.

Sanofi-Aventis plans $2.6 billion counterbid for Zentiva

June 18, 2008

The move would take Sanofi deeper into the field of generic drug production, an area which has traditionally been shunned by large pharmaceutical companies but is now receiving increased interest as a way to tap booming emerging markets.

Boehringer Ingelheim to buy Actimis Pharmaceuticals

June 17, 2008

Boehringer Ingelheim GmbH said it has agreed to take over U.S. company Actimis Pharmaceuticals Inc. for up to $515 million, to bolster its research into respiratory diseases, one of the drug maker's main areas of business.

The purchase will be carried out in gradual steps and Boehringer will pay the full price and buy all of Actimis shares if its experimental asthma treatment AP768 progresses from the first phases of testing on humans to the third and final phase, the companies said in a joint statement.

Fontus acquires nephrology and endocrinology drug from Roche

June 17, 2008

Acquired ROCALTROL (calcitriol) from Roche Laboratories Inc. ROCALTROL is a vitamin D analog prescribed by nephrologists for the management of hyperparathyroidism and resultant metabolic bone disease in patients with moderate to severe chronic renal failure (CRF) and by endocrinologists for the management of hypocalcemia in patients with post-surgical hypoparathyroidism, idiopathic hypoparathyroidism and pseudohypoparathyroidism.

GlaxoSmithKline signs superbug drug alliance with Mpex Pharmaceuticals

June 16, 2008

Under the terms of the agreement, Mpex will grant GlaxoSmithKline rights to product candidates developed under the collaboration that are directed to three different target product profiles and with the potential to deliver up to seven treatment options.

Mpex will be responsible for the discovery of EPI drug candidates and the development of combination product candidates through clinical proof of concept, at which point GlaxoSmithKline will have an option to exclusively license each product candidate for further development and commercialization on a worldwide basis.

Mpex will retain the right to further develop and commercialize product candidates for which GlaxoSmithKline does not exercise its option. Mpex will receive an $8.5 million upfront payment and a $6.5 million equity financing commitment from GlaxoSmithKline.

Contingent on achieving certain milestones, Mpex is eligible to receive development, regulatory and commercial milestones ranging up to $200 to $250 million for each product candidate. If GlaxoSmithKline exercises its option, Mpex will receive tiered royalties, which are dependent on sales achieved, for EPIs used in combination with commercially available antibiotics and with proprietary GSK antibiotics.

NovaMed appointed by Pfizer China & Baxter China as their exclusive strategic partner for selected oncology products in China

June 13, 2008

The agreement indicates that NovaMed will serve as Pfizer China’s sole distributional and promotional partner for six of its oncology products throughout mainland China starting June, 2008. It is the first alliance of its kind for Pfizer China’s oncology portfolio.

Rumour: Pfizer may make counter bid for Ranbaxy

June 13, 2008

Pfizer may bid for Ranbaxy Laboratories, countering a $4.6 billion offer by Japan's Daiichi Sankyo for the Indian generic drug maker, the Business Standard newspaper claimed.

Eli Lilly and TransPharma Medical announce licensing and development agreement

June 12, 2008

Under the terms of the agreement, Lilly will obtain exclusive worldwide rights to TransPharma's ViaDerm-hPTH (1-34) product and will also gain non-exclusive access to TransPharma's ViaDerm drug delivery system. TransPharma will receive a $35 million upfront payment, and may also receive development and sales milestones, as well as royalties on sales if a transdermal PTH product is successfully commercialized.

TransPharma and Lilly will both fund and participate in Phase II clinical development activities. Thereafter, Lilly will be responsible for further development activities and the potential commercialization of any transdermal PTH products.

Pfizer and the University of Pennsylvania announce $15 million partnership

June 12, 2008

Under the terms of the agreement, Pfizer will pay Penn $15 million over a three-year period, during which time scientists from Pfizer and Penn’s School of Medicine will work together on several projects of mutual interest including basic and translational research addressing several therapeutic areas. Project proposals will be solicited and reviewed by a committee with representation from both parties. The initial emphasis of the collaboration will focus on the neurosciences and oncology, but may expand to other areas.

Ranbaxy to bring in Daiichi Sankyo as majority partner

June 11, 2008

A binding Share Purchase and Share Subscription Agreement was entered into between Daiichi Sankyo, Ranbaxy and the Singh family, the largest and controlling shareholders of Ranbaxy.

Pursuant to the Agreement, Daiichi Sankyo will acquire the entire shareholding of the Sellers in Ranbaxy and further seek to acquire the majority of the voting capital of Ranbaxy at a price of Rs737 per share with the total transaction value expected to be between US$3.4 to US$4.6 billion. On the post-closing basis, the transaction would value Ranbaxy at US$8.5 billion.

Cellectricon and AstraZeneca partner in new high throughput ion channel drug discovery technology

June 11, 2008

Under the agreement Cellectricon will provide AstraZeneca with two of its new groundbreaking high throughput platform, Dynaflow HT, for ion channel screening.

NOXXON Pharma in licensing and discovery collaboration with Eli Lilly

June 11, 2008

Under the terms of the agreement NOXXON grants Lilly an exclusive worldwide license to a novel pre-clinical Spiegelmer, and will use its Spiegelmer technology to identify follow-on inhibitors.

Lilly will conduct all pre-clinical and clinical development as well as the worldwide commercialization of products.

NOXXON stands to receive an initial payment, committed research funding, and milestones for the achievement of specified research and development events. In addition, NOXXON is eligible to earn royalties on worldwide sales of products commercialized by Lilly as a result of this collaboration.

QLT in agreement to sell Aczone to Allergan

June 10, 2008

Under the terms of the agreement, QLT will receive a one-time cash payment of approximately US$150 million upon closing, which is expected to occur in the third quarter of 2008.

Pfizer completes acquisition of Encysive

June 10 ,2008

In the merger, each share of Encysive’s outstanding common stock was cancelled and (except for shares held by Encysive, Pfizer or by their wholly-owned subsidiaries or by holders who properly exercised their appraisal rights under Delaware law) converted into the right to receive $2.35 per share in cash, without interest and less any required withholding taxes. Prior to the merger, Explorer Acquisition Corp. acquired approximately 85.33% of the outstanding Encysive shares by tender offer.

Merck KGaA buys rights to market 30 Bristol-Myers Squibb drugs in Latin America

June 10, 2008

The sales agreement, which covers treatments of cardiovascular and metabolic conditions, runs for three years and can be extended by mutual agreement, the German drug and chemical company said in a statement.

Bristol-Myers Squibb generated more than $90 million in revenues in the region from the drugs covered by the contract last year, Merck added.

WuXi PharmaTech expands collaboration with AstraZeneca

June 10, 2008

Under the new collaboration agreement WuXi PharmaTech will synthesize compounds, according to AstraZeneca's designs, which will further expand AstraZeneca's global compound collection.

Otsuka and UCB to co-develop and co-promote Keppra and Cimzia in Japan

June 10, 2008

UCB and Otsuka have agreed on economic terms for Japan under which UCB receives up to EUR 113 million upfront and milestone payments as well as funding for the clinical development of Keppra and Cimzia.

OncoMethylome in licensing and testing agreement with Merck KGaA

June 10, 2008

Under the terms of the agreement, OncoMethylome will provide MGMT gene promoter methylation testing services for Merck's clinical trial program of cilengitide.

As part of the agreement, Merck received a worldwide, non-exclusive license from OncoMethylome to use the results of the OncoMethylome MGMT gene promoter methylation assay for optimizing glioblastoma multiforme treatment with cilengitide.

Symphogen in strategic collaboration with Genentech for antibody therapeutics in infectious disease

June 10, 2008

In this collaboration, Symphogen will apply its proprietary Symplex antibody discovery technology platform to identify novel infectious disease drug candidates. Furthermore, Genentech will gain access to Symphogen’s Sympress technology to produce recombinant polyclonal antibodies.

Under the terms of the agreement, Genentech will make an undisclosed upfront payment to Symphogen, as well as an equity investment in Symphogen. In addition, Symphogen is eligible to receive milestone payments upon the success of certain research and development milestones, as well as royalties on any products developed and commercialized by Genentech as a result of this collaboration. The total value of the agreement has the potential to exceed $330 million, and Genentech will obtain an exclusive worldwide license to candidates developed through this agreement and will fund associated research and development costs.

Pfizer and University of California, San Francisco form alliance to advance a broad range of research

June 10, 2008

The three year agreement, with research and other support up to $9.5 million, establishes a university team to help identify promising areas of mutual interest and facilitate project management. The innovative effort already has templates in place to allow swift industry-university agreements.

Allergan to buy QLT's acne gel

June 9, 2008

Under the terms of the agreement, QLT will receive a one-time cash payment of approximately US$150 million upon closing, which is expected to occur in the third quarter of 2008.

Akela amends licensing and development agreement with Janssen

June 9, 2008

The amendments to the original agreement were made in support of the clinical program and commercial scale manufacturing and to secure timely advancement of the Phase III clinical trials. A milestone of (euro) 4.5 MM (Approx. USD $7 MM) will be advanced to the beginning of the Phase III trial.

The milestone of (euro) 2.5 MM (Approx. USD 4 MM), due as of the inclusion of the 7th patient in the study remains unchanged. Both amounts will go directly towards supporting our Fentanyl TAIFUN(R) development program.

Astex Therapeutics in drug discovery alliance with Janssen

June 9, 2008

Under the terms of the agreement, Ortho Biotech Research & Development, the research and development arm of Janssen Pharmaceutica, will be responsible for completing all of the preclinical and clinical development of all products arising from the collaboration and for their commercialisation globally. The agreement also grants Astex an option to co-commercialise FGFR products developed under the collaboration in the USA.

The agreement provides for an upfront payment and equity investment in Astex, plus committed research funding, totalling $37.4 million over a two year period, as well as downstream development and regulatory milestones relating to all three programmes. Astex will also receive tiered, double digit, royalties on sales of FGFR inhibitor products discovered and developed under the collaboration and additional royalties on new products generated under the other research programmes. Total payments under the collaboration, excluding royalties, could be worth over $500 million to Astex, assuming one product from each programme is successfully commercialised in all territories.

Ipsen in definitive merger agreement with Tercica

June 5, 2008

A subsidiary of Ipsen has entered into a definitive merger agreement by which it will acquire the remaining approximately 44.9 million fully diluted shares of Tercica not owned by the Ipsen group for $9.0 per share in cash, for a total purchase price of approximately $404 million.

Ipsen acquires US operations of Vernalis

June 5, 2008

Ipsen has agreed with Vernalis to acquire all the shares of its US subsidiary Vernalis Inc, and to acquire from its UK subsidiary Vernalis (R&D) Limited the rights and assets required to develop and market Apokyn in the US, for a total consideration of up to $12.5 million (or EUR 8.1 million).

In this context, Ipsen will pay $6.5 million to Vernalis plc (or EUR 4.2 million) in upfront payments and additional payments of up to $5.0 million (or EUR 3.2 million) contingent on certain commercial and operating milestones. In order to demonstrate its commitment to the business, Ipsen will also underwrite before closing $2.2 million (or EUR 1.4 million) of specific corporate and commercial expenses of Vernalis Inc.

Ipsen and Vernalis plc have also agreed to negotiate a joint venture to raise funding for the development of a selection of Ipsen's neurology pipeline projects. If this does not proceed, Ipsen will make a payment of $1.0 million to Vernalis.

Ipsen in purchase agreement with Octagen to acquire all its OBI-1 related assets

June 5, 2008

Ipsen and Octagen have entered into an Asset Purchase Agreement pursuant to which Ipsen will, upon closing, acquire all of Octagen's assets related to OBI-1 and get full control over OBI-1's clinical development.

Pursuant to the Asset Purchase Agreement announced today, upon closing, Ipsen will make an upfront payment of $10.5 million (EUR 6.8 million) to Octagen. Also Ipsen will make future additional milestone payments contingent on the product being allowed into Phase III, and later on receipt of marketing approvals in the U.S. and Europe, potentially totaling up to $26.0 million (EUR 16.8 million). In addition, Ipsen shall pay, once the product is marketed and for a defined duration, a low to mid single digit royalty on its net sales in each country, on an upward sliding scale depending on certain sales thresholds.

Immediately following the completion of the acquisition of all of the assets related to OBI-1, Ipsen will also redeem its stake in Octagen.

Pfizer licenses Ariadne Genomics Pathway Studio Enterprise

June 5, 2008

Pfizer has purchased a multi-site license for Pathway Studio Enterprise. Pfizer is going to use it to assemble reference networks of biological interactions from internal and public data sources for interpretation of experimental results throughout its research facilities.

ChemDiv to provide Schering-Plough with discovery libraries

June 5, 2008

ChemDiv will provide Schering Plough with a set of chemical libraries that will be produced through parallel synthesis based on the customer selected templates. In accordance with the agreement teams of ChemDiv and Schering Plough scientists will work closely to develop exclusive small molecule libraries enhancing Schering Plough's global drug discovery effort.

GlaxoSmithKline in licensing agreement with Compendia Bioscience

June 5, 2008

A two-year licensing agreement with GlaxoSmithKline for Oncomine Enterprise Edition, a value-added product extension Compendia's flagship product, Oncomine.

Novartis to acquire Protez Pharmaceuticals for up to $400million

June 4, 2008

Novartis will acquire Protez for up to $400 million in cash, of which $100 million will be paid at closing and of up to $300 million will be paid if certain clinical milestones, regulatory approvals and commercial targets are achieved. Protez will become a stand-alone subsidiary of Novartis, maintaining its operations in Malvern, Pennsylvania. The transaction is subject to customary closing conditions.

The agreement provides Novartis with Protez’s research expertise and product pipeline including the North American and European rights to its lead product candidate PZ-601, an injectable antibiotic in the class of agents known as carbapenems.

GlaxoSmithKline and Immune Disease Institute In $25M Partnership

June 4, 2008

GlaxoSmithKline and the Immune Disease Institute have announced a five year collaboration worth $25 million to build a unique partnership in immunoinflammation research.

The collaboration aims to combine IDI’s world-class immunological expertise with GSK’s pharmaceutical capabilities within a competitive framework. The partnership will be pioneering in the way it allows researchers at both institutions to develop joint grant proposals in targeted areas of research under an innovative and competitive Alliance Research grant program. In addition to the substantial scientific benefits brought by a long-term synergy with world class immunologists, GSK will receive an exclusive Right of First Negotiation for a substantial portion of the new technologies discovered and disclosed by IDI scientists during the term of the agreement. The research term for the collaboration is five years and will be anchored through GSK’s Immuno-Inflammation Centre of Excellence in Drug Discovery (II CEDD).

Ingenuity Systems in multi-year agreement with Boehringer Ingelheim

June 4, 2008

The agreement provides global access for Boehringer Ingelheim research scientists to access to the recently released IPA 6, which includes new biological and chemical content, in addition to Path Designer, an award-winning set of tools that more clearly communicates information about networks and pathways.

GeneGo extends agreement with Merck

June 3, 2008*

This agreement provides Merck with access to GeneGo's content through MetaBase which includes access to MetaCore and MetaDrug content and GeneGo's internal database of disease biomarkers.

Vertex sells HIV product royalty stream to GlaxoSmithKline

June 3, 2008

Vertex has sold its rights to future royalties in Lexiva and Agenerase under its 1993 license agreement with GlaxoSmithKline in the field of HIV protease inhibitors for a one-time cash payment of $160 million.

In 2007, Vertex received net HIV royalty revenue of $34.1 million, based on royalties of $48.0 million from GSK, and $13.9 million in royalty payments made by Vertex to a third party with respect to this license agreement. As a result of the sale of the future royalties, Vertex will no longer make royalty payments to the third party with respect to Lexiva and Agenerase.

Mylan acquires Central Eastern European generics businesses of Merck KGaA

June 2, 2008

Mylan has acquired Merck KGaA's Central & Eastern Europe (CEE) generics businesses, which include operations in Poland, Hungary, Slovakia, Slovenia and the Czech Republic. As announced previously, Mylan exercised its option to acquire these businesses as part of the original, October 2007 agreement in which Mylan acquired Merck KGaA's generics business (Merck Generics) in Western Europe, Asia-Pacific, Africa and North America.

Roche signs exclusive distribution deal With DxS for K-RAS and EGFR cancer mutation tests

June 2, 2008

Under the terms of the agreement, Roche is granted exclusive world-wide distribution rights for the K-RAS Test, which has CE Mark certification in Europe. For the EGFR test, which also has CE Mark certification, Roche is granted exclusive distribution rights for all global markets except the United States, Canada, Mexico, and Hong Kong.

May 2008

Gilead Sciences and Navitas in agreement for Cicletanine for treatment of pulmonary arterial hypertension

May 30, 2008

Under the terms of the agreement, Gilead will pay Navitas an upfront payment and contingent payments on future net sales. Navitas also could earn additional payments based upon the achievement of certain development and regulatory milestones. Gilead has acquired the exclusive rights to regulatory data and filings for development of cicletanine as a monotherapy for PAH and for other indications in the United States.

PsychoGenics and Roche enter agreement to identify new treatments for neuropsychiatric disorders

May 29, 2008

The agreement provides that Roche will provide drug candidates and PsychoGenics will evaluate these candidates, using its proprietary drug discovery technologies, for the treatment of neuropsychiatric disorders. Either party has the option to exclusively develop any drug candidate emerging from this collaboration, with the non-developing party receiving milestones and royalties commensurate with the stage of development.

Bristol-Myers Squibb to acquire KOSAN Biosciences

May 29, 2008

The transaction, with a net aggregate purchase price of approximately $190 million after deducting Kosan’s projected net cash balance at June 30, 2008, has been unanimously approved by the boards of directors of both companies.

The acquisition of Kosan will enhance Bristol-Myers Squibb’s pipeline with compounds in two important classes of anticancer agents: novel Hsp90 (heat shock protein 90) inhibitors and epothilones.

Merck KGaA and Caprotec Bioanalytics sign collaboration agreement

May 28, 2008

Under the terms of the agreement caprotec will apply its Capture Compound Mass Spectrometry technology to identify relevant protein – drug molecule interactions for one of Merck Serono’s research projects. caprotec will receive research funding and potential milestone payments on product development.

Alnylam and Takeda sign strategic platform alliance in RNAi therapeutics

May 27, 2008

A strategic platform alliance in RNAi therapeutics in the fields of oncology and metabolic disease with the option to expand to additional therapeutic areas. This landmark alliance is the first major RNAi therapeutics partnership between a Japanese pharmaceutical company and a US biotechnology company, representing a new frontier in the advancement of RNAi therapeutics to patients on a global basis.

The partnership includes $100 million in upfront payments and $50 million in near-term technology transfer payments for a non-exclusive license in two therapeutic fields and is valued at potentially over $1 billion in future research and development and commercial milestones, upon successful commercialization of multiple products.

At Takeda’s option, the scope of the partnership can be expanded to include additional fields with a $50 million per field expansion payment. Alnylam is also eligible to receive research and development funding related to the drug discovery collaboration.

In addition, Alnylam is eligible to receive up to $171 million in development and commercial milestone payments and significant royalties per product.

GVK BIO in drug discovery pact with Wyeth

May 27, 2008

GVK BIO will be responsible for identifying drug candidates, which will be transferred to Wyeth to advance these compounds towards clinical studies. Under the agreement, GVK BIO will receive an initial payment and will be eligible for success-based milestone payments.

King exercises option to license third opioid product from Acura

May 27, 2008

King and Acura entered into a License, Development and Commercialization Agreement in October 2007. The Agreement provides King with an exclusive license to ACUROX tablets and another undisclosed opioid product, and an option to license all future opioid analgesic products formulated with Acura's AVERSION Technology.

In connection with the exercise of its option for this third opioid product under the Agreement, King paid Acura an option exercise fee of $3.0 million. As a result, the companies are now jointly developing three immediate-release opioid analgesics utilizing Acura's AVERSION Technology, which is designed to resist or deter common methods of prescription drug misuse and abuse.

Indevus licenses Canadian rights for Sanctura XR to Allergan

May 22, 2008

Indevus and Rottapharm Madaus will share equally in the proceeds from the license transaction. Under the terms of the agreement, Allergan will pay up to $9 million to each of Indevus and Rottapharm Madaus, including a $7 million up-front license fee and up to $2 million in sales threshold milestone payments. Allergan will be responsible for all regulatory and marketing activities in Canada.

Myriad Genetics selects H. Lundbeck A/S as European partner for Flurizan

May 22, 2008

Myriad and Lundbeck have entered into a European commercialization agreement under which Lundbeck will have rights to market and sell Flurizan in the European Union and several associated non-EU countries and will manage the regulatory process.

Lundbeck has agreed to pay Myriad an initial $100 million and will pay up to $250 million in connection with regulatory approvals. Furthermore, Lundbeck has agreed to pay attractive commercialization milestones and will purchase bulk pharmaceutical material from Myriad. Lundbeck has also agreed to pay escalating royalties of 20 - 39% on sales, less the amount paid for the bulk drug.

Thales Nanotechnology and Sanofi-Aventis collaborate on continuous process chemistry

May 22, 2008

The collaboration will focus on the development and implementation of continuous process technologies from research to full-scale production. The purpose of the project is to study the utilization and application of ThalesNano's integrated continuous process chemistry technologies within the sanofi-aventis drug R&D process from discovery to API production.

Daiichi Sankyo to buy U3 Pharma

May 21, 2008

Daiichi Sankyo will purchase 100 percent of the stock and make a one-time payment of 150 million Euros ($235 million dollars) for the company. Closure of the transaction is subject to clearance under the Hart-Scott-Rodino Antitrust Improvements Act and customary closing conditions.

Rentschler Biotechnologie in cooperation with Boehringer Ingelheim

May 21, 2008

The cooperation will enable Rentschler Biotechnologie’s clients to gain access to Boehringer Ingelheim’s large-scale mammalian biopharmaceutical production facilities in Biberach, Germany and vice versa, Boehringer Ingelheim’s clients to use Rentschler’s facilities of process development and intermediate-scale clinical supply production.

Five Prime Therapeutics and Pfizer enter oncology and diabetes collaboration

May 20, 2008

Upon the commencement of the collaboration, FivePrime will receive an up-front payment and an equity investment from Pfizer and three years of committed research funding. Pfizer will have exclusive worldwide rights to develop and commercialize certain products and targets discovered during the research term, in exchange for future milestones and royalties. Further details of the agreement have not been disclosed.

BioSeek to collaborate with Merck Serono to assess potential drug candidates

May 20, 2008

Under the collaboration, BioSeek will apply its BioMAP Systems to evaluate Merck Serono small molecule compounds and proteins across multiple therapeutic areas in support of target differentiation, lead selection, and nomination of candidates for preclinical development at Merck Serono. Financial details were not disclosed.

Schering-Plough extends MorphoSys alliance

May 19, 2008

The collaboration, announced in May 2006, has a maximum term of 5 years until 2011 and may be extended by Schering-Plough after each single year.

Under the agreement, Schering-Plough will continue to have access to MorphoSys's proprietary antibody library HuCAL GOLD at its research site in Palo Alto, California, the location of Schering-Plough Biopharma, an affiliate of Schering-Plough Research Institute. Furthermore, the contract provides Schering-Plough with the option to develop and commercialize HuCAL-derived therapeutic antibodies, in which case MorphoSys would receive exclusive license fees, milestone payments, as well as royalties.

Under the extended agreement MorphoSys continues to receive annual user fees for access to its HuCAL platform.

Intellect Neurosciences grants patent license to Wyeth and Elan

May 19, 2008

Intellect Neurosciences has entered a license agreement with Wyeth and Elan Pharma regarding certain of Intellect's patents and patent applications related to antibodies and methods of treatment for Alzheimer's disease.

Under the terms of the agreement, Wyeth and Elan may pay Intellect potential future milestone payments and royalties based on sales of potential products, if it is determined that they are covered by patents that issue from Intellect's patent applications.

Rumour mill: Pfizer eyes Germany's MediGene

May 14, 2008

Pfizer is exploring acquisition possibilities in the German biotech sector and has held talks with the management of Munich-based MediGene, two industry sources said.

BMS and KAI Pharmaceuticals in global alliance to develop and commercialize KAI-9803 for cardiovascular disease

May 13, 3008

Under the terms of the collaboration, KAI will receive an upfront cash payment of $25 million. Bristol-Myers Squibb will fund all future development, including the Phase 2b clinical trial to be conducted by KAI.

In addition, at KAI’s option, Bristol-Myers Squibb will purchase $10 million of KAI stock at the time of a qualified initial public offering, or under other specified future conditions. KAI may receive from Bristol-Myers Squibb up to $192 million in milestone payments based on the achievement of pre-specified development and regulatory milestones for KAI-9803.

KAI could be eligible for additional milestones if other compounds are developed. KAI will have an option to co-promote KAI-9803 in the United States and will receive royalty payments on product net sales worldwide.

Ranbaxy signs drug discovery development pact with Merck & Co

May 12, 2008

Ranbaxy and Merck will work together to develop clinically validated anti-bacterial and anti-fungal drug candidates. Ranbaxy will carry-out drug discovery and clinical development through Phase IIa clinical trials, with Merck conducting development and commercialization of drug candidates thereafter.

The Agreement provides that the collaboration will begin this year with an initial term of five years and can be extended mutually thereafter by the parties.

Under the terms of the Agreement, Ranbaxy will be paid an undisclosed upfront sum, with the potential to receive payments totaling more than US$100 million associated with the achievement of various research, development and regulatory approval milestones for each target included in the collaboration. Ranbaxy is also eligible to receive significant royalties on worldwide net sales of any products commercialized under the Agreement.

Forest and Daiichi Sankyo terminate AZOR co-promotion agreement

May 12, 2008

The AZOR agreement is the second co-promotion agreement for the two companies. A previous agreement signed in 2002 by Forest to co-promote Benicar and Benicar HCT is currently still in force.

That agreement specified a co-promotion period, which has been extended to end on May 31, 2008, and a residual period where Forest will continue to receive income from Benicar and Benicar HCT profits, which doesn't expire until March 31, 2014.

Forest has determined that the resources it has allocated to the AZOR co-promotion will be better utilized in providing additional support for Forest's currently marketed products.

SomaLogic and Otsuka enter research collaboration

May 12, 2008

Under the terms of the agreement, SomaLogic will receive committed research funding and will be entitled to receive a royalty on any marketed products developed as a result of the collaboration. Otsuka also received an option to acquire distribution rights in Asia for certain SomaLogic clinical diagnostics products. In addition, SomaLogic received an equity investment from Otsuka.

ACT Biotech acquires clinical and early stage oncology portfolio licenses from Bayer HealthCare

May 7, 2008

Under the terms of the license agreement with Bayer, ACT Biotech has acquired an anti-angiogenic receptor tyrosine kinase inhibitor entering Phase II clinical studies for colorectal cancer, amongst other indications.

An additional program in-licensed in this agreement is a first-in-class multi-mode kinase inhibitor in late preclinical stage with application in a variety of cancer types. The company also acquired several additional preclinical stage programs in oncology.

As part of the agreement, Bayer will maintain a minority equity stake in ACT Biotech.

Bristol-Myers Squibb to sell ConvaTec unit for $4.1 billion

May 5, 2008

Definitive agreement to sell its ConvaTec business unit to Nordic Capital Fund VII and Avista Capital Partners for $4.1 billion subject to adjustments based on ConvaTec’s audited 2007 financial statements and closing working capital.

Galapagos and Allergan enter drug discovery collaboration

May 5, 2008

Total contract value for Galapagos could reach up to EUR 1.3 million over the next 12 months, contingent on the number of BioFocus DPI compounds screened.

QSV Biologics awarded cGMP manufacturing contract by Pfizer

May 2, 2008

cGMP manufacturing contract for a recombinant protein under development by Pfizer, Inc. The protein will be manufactured at QSV's Edmonton facility and is intended for clinical trials. Work on the project is to begin immediately, and will include technology transfer, scale-up and cGMP manufacturing.

Roche exercises option to develop and commercialize Memory Pharmaceuticals nicotinic alpha-7 agonist, MEM 3454

May 2, 2008

Roche's exercise of its option for MEM 3454 triggers a $6 million milestone payment and entitles Memory Pharmaceuticals to future payments upon the achievement of additional milestones and royalties on product sales, including a $17 million milestone payment upon the completion of the ongoing Phase 2a study in cognitive impairment associated with schizophrenia (CIAS).

In addition, Memory Pharmaceuticals retains an option to co-promote MEM 3454 in the United States.

Abbott and Takeda Pharmac conclude TAP joint venture

May 1, 2008

The closing of the agreement to evenly divide the value of the more than 30-year-old joint venture marks the conclusion of one of the most successful joint ventures in the history of American business.

Under terms of the agreement, Abbott receives rights to the oncology treatment, Lupron, including the commercial organization supporting that franchise, and will receive payments based on TAP's other current and certain future products. Takeda receives the rights to the product Prevacid, all the remaining TAP commercial and support organizations, and the rights to TAP's pipeline.

Entelos enter in silico research agreement with Eli Lilly

May 1, 2008

Agreement with Entelos to conduct in silico research in the field of diabetes using the Entelos Metabolism PhysioLab platform. Financial terms were not disclosed.

April 2008

Pfizer partners with Revolution Computing to improve medicine production pipeline

April 29, 2008

REvolution Computing worked with Pfizer to parallelize its software solution called caret. The parallel caret package, caretNWS, provides parallel processing functionality that allows users the possibility of greatly reducing the computational time to build models without sacrificing model quality.

Pfizer enters research consortium in diabetes and obesity pathobiology

April 27, 2008

Pfizer is funding the three-year and $14 million Insulin Resistance Pathway Project to look at insulin signaling in adipose cells to increase understanding of diabetes and obesity.

Astellas Pharma and CoMentis in Alzheimer's deal

April 25, 2008

CoMentis will receive an upfront payment of $80 million and an equity investment of $20 million. CoMentis has the opportunity to receive up to $660 million in development milestones and may also receive performance-based commercialization milestones.

In addition, CoMentis has the right to receive development milestones for next-generation beta-secretase inhibitors discovered under the terms of the research collaboration. Astellas will fund 100% of the pre-Phase III global development costs and CoMentis will share the Phase III development costs.

Astellas has exclusive worldwide commercialization rights while CoMentis retains the right to co-promote in the U.S., where profit will be shared. CoMentis will receive royalties on sales outside the US.

Arana Therapeutics and Kyowa Hakko to co-develop anti-cancer drug

April 24, 2008

Arana will receive an upfront US$4 million payment and additional milestones of up to US$4 million. ART104 will be enhanced using Kyowa Hakko’s proprietary POTELLIGENT and COMPLEGENTTM Technologies. Arana and Kyowa Hakko will have equal ownership of the product and will equally share development costs.

Kyowa Hakko has an option to develop and commercialise the product in some Asian markets such as Japan, South Korea, Taiwan and China. Arana will receive royalties on these sales.

Shire acquires new clinical candidate for metachromatic leukodystrophy

April 24, 2008

Shire is making a payment to Zymenex of US$135 million for the acquisition of global rights to the product upon completion of the transaction, which is conditional upon the receipt of customary consents.

Zymenex is also providing certain transition services, including know-how transfer, for up to six months after completion. The transaction includes no royalties or other downstream payment obligations.

GlaxoSmithKline to acquire Sirtris Pharmaceuticals

April 23, 2008

GlaxoSmithKline will acquire Sirtris Pharmaceuticals for approximately USD720 million through a cash tender offer.

Through the acquisition of Sirtris, GSK will significantly enhance its metabolic, neurology, immunology and inflammation research efforts by establishing a presence in the field of sirtuins, a recently discovered class of enzymes that are believed to be involved in the ageing process.

Sirtris will become part of GSK's Drug Discovery organisation, while continuing to operate from laboratories in Cambridge, Massachusetts as an autonomous drug discovery unit.

Pfizer Animal Health to acquire animal health products from Schering-Plough

April 24, 2008

Pfizer Animal Health will acquire from Schering-Plough a number of animal health products for sale in the European Economic Area covering swine E. coli vaccines, equine influenza and tetanus vaccines, ruminant neonatal and Clostridia vaccines, rabies vaccines, companion animal veterinary specialty products, parasiticides, and anti-inflammatories.

Metabasis extends collaboration with Merck to develop AMPK activators for diabetes and other metabolic diseases

April 23, 2008

Merck and Metabasis will continue to work collaboratively with the goal of producing a candidate molecule suitable for clinical development. Merck will continue to fund research efforts at Metabasis for this project and has primary responsibility, including financial responsibility, for clinical development of any resulting therapeutic candidates as well as the right to market any products derived from the collaboration worldwide.

Metabasis is eligible to receive payments upon achievement of certain candidate development milestones. Should a product be commercialized, Metabasis will receive a royalty on net sales and have the option to co-promote the product in the United States. Metabasis will receive $1.5 million over the course of the one-year extension to support its research efforts.

Human Genome Sciences reacquires GlaxoSmithKline rights to TRAIL receptor antibodies in return for reduction in Syncria royalties

April 17, 2008

The GSK rights to the TRAIL receptor antibodies resulted from a June 1996 agreement under which HGS granted a 50/50 co-development and co-promotion option to GSK for certain human therapeutic products that complete Phase 2a clinical trials.

In exchange for reacquiring the rights to its TRAIL receptor antibodies, HGS has agreed to a reduction in the royalties to which it is entitled from GSK if Syncria is commercialized. The fees and milestone payments due to HGS under the original Syncria agreement, some of which have already been received, could amount to as much as $183 million and remain unchanged in the amended agreement.

Washington University and AstraZeneca in Alzheimer's research collaboration

April 17, 2008

The major focus of the alliance will be biomarkers, characteristic changes in the brain and spinal fluid, that physicians can use to diagnose Alzheimer's disease and track its response to treatment.

Roche and the Institute for OneWorld Health in research collaboration to fight neglected diarrheal diseases in developing countries

April 17, 2008

OneWorld Health will screen compounds from the Roche library to identify a potential new drug for the treatment of diarrheal diseases, which kills approximately 2 million children under the age of five in developing countries each year.

GlaxoSmithKline boosts biotech with $600M Regulus deal

April 17, 2008

The alliance leverages Regulus’ unique expertise and intellectual property position in the discovery and development of microRNA-targeted therapeutics and provides GSK with an option to license product candidates directed at four different microRNA targets with relevance in inflammatory disease. Regulus will be responsible for the discovery and development of the microRNA antagonists through completion of clinical proof of concept, unless GSK chooses to exercise its option earlier. After exercise of the option, GSK will have an exclusive license to drugs developed under each program by Regulus for the relevant microRNA target for further development and commercialization on a worldwide basis. Regulus will have the right to further develop and commercialize any microRNA therapeutics which GSK chooses not to develop or commercialize.

Regulus will receive $20 million in upfront payments from GSK, including a $15 million option fee and a $5 million note (guaranteed by Isis and Alnylam) that will convert into Regulus common stock in the future under certain specified circumstances. Regulus could also be eligible to receive up to $144.5 million in development, regulatory and sales milestone payments for each of the four microRNA-targeted therapeutics discovered and developed as part of the alliance. In addition to the potential of nearly $600 million Regulus could receive in option, license and milestone payments, Regulus would also receive tiered royalties up to double digits on worldwide sales of products resulting from the alliance.

Pfizer and AVANT in licensing and development deal for for brain cancer

April 17, 2008

Under the licensing and development agreement, Pfizer will make an upfront payment to AVANT of $40 million and will make a $10 million equity investment in AVANT. Pfizer will fund all development costs for these programs.

AVANT is also eligible to receive milestone payments exceeding $390 million for the successful development and commercialization of CDX-110 and additional EGFRvIII vaccine products, as well as double-digit royalties on any product sales.

The agreement is subject to approval under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 (as amended) and is expected to close in the second quarter of 2008.

Pelikan and Eli Lilly form alliance

April 16, 2008

Under the terms of the co-promotion agreement, the companies will promote awareness and education in the management and treatment of diabetes, including insulin therapy, insulin delivery devices and technological advancements in lancing designed to optimize Finger Health and Glucose Monitoring.

Medivir enters co-promotion agreement with GlaxoSmithKline

April 15, 2008

The agreement provides Medivir the right to co-promote some of GSK’s products on the Swedish market.

The products covered by the agreement include GSK’s entire dermatology portfolio, certain anti-infective products and smoking cessation aid Zyban.

Ingenuity Systems Pfizer in strategic partnership

April 15, 2008

This new multi-year partnership promotes enterprise-wide deployment of IPA, enabling more researchers to use IPA for the exploration, interpretation, and analysis of life science information. In addition, Pfizer will integrate IPA and content from the Ingenuity knowledge base with other informatics solutions used throughout the Pfizer organization.

Roche acquires PIramed for $160M

April 15, 2008

Roche Holding is buying privately owned British biotechnology company Piramed for $160 million to acquire its treatments against cancer and immune inflammatory disorders like arthritis and asthma.

PDI to promote Novartis branded product in USA

April 11, 2008

Four-year agreement with Novartis, whereby PDI will deploy a field force to promote a Novartis branded product in the United States.

Celera grants license to Merck & Co for cancer targets

April 10, 2008

Under the terms of the agreement, Merck will pay Celera a license fee for the exclusive access to the ten targets, in addition to the payment of development and commercial milestones plus royalties on selected targets that it advances successfully.

Merck also has the option to extend the exclusivity period or add additional targets. Financial terms of the agreement were not disclosed.

Celera will be able to develop and commercialize related companion diagnostics, or theranostics, that are specific to certain therapeutic candidates arising from Merck’s program.

Takeda to buy Millennium for $8.8 billion

April 10, 2008

Takeda Pharmaceutical Company Limited and Millennium Pharmaceuticals, Inc. today announced that they have entered into a definitive agreement pursuant to which Takeda will acquire Millennium for approximately $8.8 billion through a cash tender offer of $25.00 per share.

The transaction was unanimously approved by the Boards of Directors of both companies. Upon completion of the acquisition, Millennium will become a wholly-owned subsidiary of Takeda Pharmaceutical Company Limited, and will continue operations in Cambridge, Massachusetts, as a standalone business unit.

Millennium will be known as Millennium Pharmaceuticals, Inc., a Takeda Company.

Harvard University in collaboration with Merck to advance osteoporosis research

April 9, 2008

Under the agreement, Merck will fund ongoing research in the laboratory of Laurie Glimcher, MD, the Irene Heinz Given Professor of Immunology at Harvard School of Public Health, and a Professor of Medicine at Harvard Medical School, and will be granted a license to certain specific molecules that may arise from this project.

BMS selects Isis drug targeting Pcsk9 as development candidate for cardiovascular disease

April 8, 2008

Isis will receive a $2 million milestone payment. The two companies have an ongoing collaboration to identify antisense drugs that target proprotein convertase subtilisin kexin 9 (PCSK9). The development candidate is an antisense inhibitor of PCSK9 that helps regulate the amount of cholesterol in the bloodstream.

Novartis to buy Nestle's Alcon Laboratories Stakes for $39B

April 7, 2008

Once consummated, Novartis would own a minority stake in Alcon of approximately 25 percent of Alcon’s outstanding shares, while Nestlé would remain Alcon’s majority shareholder with approximately 52 percent of Alcon’s outstanding shares.

Nestlé and Novartis also announced that the agreement contains put and call option rights on the remaining Alcon shares owned by Nestlé, which commence on January 1, 2010 and expire on July 31, 2011. As outlined by the two parties, these rights grant (i) Novartis a call option to buy Nestlé’s remaining Alcon shares at a fixed price of $181 per share and (ii) Nestlé a put option to sell its remaining Alcon shares to Novartis at the lower of Novartis’s call price of $181 per share or at a 20.5 percent premium above the market price of Alcon shares, which will be calculated as the average price of Alcon shares during the week preceding the exercise date of the put option.

The agreement also provides for the expansion of the Alcon board of directors from eight to ten members, with one of the additional members designated by Nestlé and one designated by Novartis. The nominees for these additional board seats are James Singh, who is currently Nestlé’s executive vice president and chief financial officer, and Daniel Vasella, M.D., who is chairman and chief executive officer of Novartis. Shareholders will vote on whether to expand the Alcon board and to elect these nominees at Alcon’s upcoming Annual General Meeting which will be held on May 6, 2008, in Zug, Switzerland. Alcon distributed proxy materials to its shareholders on April 2, 2008, and it will distribute a new proxy form to shareholders incorporating these additional items.

IOMAI and Merck evaluate use of Iomai immunostimulant patch

April 3, 2008

Merck has first option to negotiate an exclusive license. These preclinical proof-of-principle studies will be conducted using an undisclosed Merck vaccine.

Cell Genesys and Takeda global alliance for development and commercialization of GVAX immunotherapy for prostate cancer

April 1, 2008

Under the agreement, in exchange for exclusive worldwide commercial rights to GVAX immunotherapy for prostate cancer, Takeda will pay Cell Genesys an upfront payment of $50 million and additional milestone payments totaling up to $270 million relating to regulatory approval and commercialization of GVAX immunotherapy for prostate cancer in the United States, European Union and Japan.

Takeda will pay Cell Genesys tiered, double-digit royalties based on net sales of GVAX immunotherapy for prostate cancer in the United States and flat double-digit royalties based on net sales of the product in all other regions. From this point forward, Takeda will pay for all external development costs associated with the ongoing Phase 3 clinical development of GVAX immunotherapy for prostate cancer and will also pay for all additional development costs and all commercialization costs.

Cell Genesys will maintain responsibility for the worldwide manufacture and supply of the product and will retain rights to co-promote GVAX immunotherapy for prostate cancer in the United States.

March 2008

Acusphere licenses hydrophobic drug delivery system to Cephalon

March 31, 2008

Agreement to license the intellectual property rights to its Hydrophobic Drug Delivery System (HDDS) for oncology applications, along with the rights to AI-850, its formulation of paclitaxel, to Cephalon, Inc., in exchange for a cash payment of $10 million.

Teva to Acquire Bentley Pharmaceuticals

March 31, 2008

The acquisition will take place following the spin-off of Bentley’s drug delivery business to its shareholders, which Bentley announced on October 23, 2007.

Teva will acquire Bentley, which at closing will consist solely of the generic pharmaceutical operations, for an aggregate cash purchase price of approximately $360 million.

Shareholders of Bentley will receive approximately $15.02 per share in cash in the acquisition (which price is subject to potential adjustment, as described below), and also will receive shares of CPEX Pharmaceuticals, Inc. pursuant to the spin-off, which will occur before the acquisition.

MethylGene in worldwide research and license agreement With Otsuka

March 27, 2008

MethylGene will be responsible for the design, synthesis, characterization and initial screening of kinase inhibitors. Otsuka will be responsible for and fund efficacy and toxicology studies, as well as preclinical and clinical development of compounds. Otsuka is also responsible for the global commercialization of any resulting product.

Under the financial terms of the agreement, MethylGene will receive an upfront license fee of US$2 million and may receive additional payments based on successful development, regulatory, commercialization and sales milestones that could total US$50.5 million.

Otsuka will also provide MethylGene with a minimum of US$1.875 million in research funding for the initial 18 months of the research collaboration, which can be extended with additional funding from Otsuka. MethylGene will receive royalties on net sales for any resulting product.

In addition, Otsuka is committed over the next 18 months to make an equity investment of US$3 million in MethylGene stock in the event the Company completes a concurrent financing of at least US$10 million and is listed on a US stock exchange; or alternatively, a US$1.5 million equity investment at a 20% premium if MethylGene is solely listed on the Toronto Stock Exchange after such 18-month period.

Shire and TAP to co-promote LIALDA

March 26, 2008

This three year agreement is for the U.S. only and will add more than 500 additional sales representatives from TAP to increase the reach and frequency of the Shire sales force, which consists of 120 representatives who are currently detailing LIALDA primarily to gastroenterologists.

Daiichi Sankyo extends alliance with MorphoSys for use of HuCAL GOLD to develop novel antibody therapies

March 26, 2008

Under the agreement, which is now extended for up to three more years until March 2011, Daiichi Sankyo will continue to have access to MorphoSys's proprietary antibody library HuCAL GOLD at its research site in Tokyo.

Furthermore, the extension includes an option for Daiichi Sankyo to develop and commercialize up to 6 HuCAL-derived therapeutic antibodies, in which case MorphoSys would receive exclusive license fees and milestone payments, as well as royalties. Today, the collaboration encompasses one active therapeutic antibody program.

The extension triggers an additional payment from Daiichi Sankyo and results in increased research funding for MorphoSys. Furthermore, under the extended agreement MorphoSys continues to receive annual user fees for access to its HuCAL platform. Further financial details were not disclosed.

genOway in master service agreement with Boehringer Ingelheim

March 26, 2008

This agreement is a master service agreement under which genOway will provide its client with customized rat lines tailored to the researchers’ needs. The agreement is a 5-year agreement.

Acambis extends Sanofi Pasteur licensing agreement for ChimeriVax-JE vaccine

March 20, 2008

Acambis will receive from Sanofi Pasteur an upfront payment, a milestone payment on licensure of the vaccine in India and royalties on sales in these territories. Bharat Biotech has made a significant contribution towards the development of ChimeriVax-JE and Acambis has agreed to compensate Bharat Biotech. The net financial effect is positive for Acambis.

Icagen and Pfizer form collaboration with Birkbeck, University of London to elucidate channel structure

March 20, 2008*

This three party relationship has been established to support a previously established collaboration between Icagen and Pfizer for the discovery of compounds which modulate specific sodium ion channels as potential new treatments for pain and related disorders.

Cenix and AstraZeneca in framework research agreement for RNAi-based drug discovery

March 19, 2008

Cenix will apply its well-established expertise in combining high throughput (HT) applications of RNAi-based gene silencing, the technology behind the 2006 Nobel Prize for Medicine, with high content phenotypic analyses in cultured human cells.

The initial project will involve a HT-RNAi screen using an assay strategy co-designed with AstraZeneca scientists to discover and validate novel oncology targets. Cenix will adapt and implement multi-parametric microscopy-based assays using the Cellenger image analysis platform from Munich-based Definiens, to generate detailed insights into the cellular functions and loss-of-function phenotypes of analyzed genes.

Takeda to buy Abbott stake in TAP

March 19, 2008

Takeda claimed to be in talks to make TAP a wholly owned unit costing it around $5 billion and aims to complete the deal by year-end.

Samaritan acquires rights to Abiogen's cancer drug Abioklad in Greece, Cyprus and Turkey

March 19, 2008

Samaritan has acquired the rights from Abiogen Pharma of Italy to distribute and sell the specialty pharmaceutical, Abioklad, in Greece, Cyprus, and Turkey.

FDA licenses Sanofi Pasteur's Daptacel vaccine

March 14, 2008

Daptacel to be administered as a fifth consecutive diphtheria, tetanus, and acellular pertussis (DTaP) vaccine dose for children 4 years through 6 years of age for the prevention of diphtheria, tetanus, and pertussis.

Eli Lilly and Transition Therapeutics announce licensing and collaboration agreement

March 14, 2008

Under the terms of the agreement, Transition will receive a $7 million upfront payment, and may also receive up to $130 million in potential development and sales milestones, as well as royalties on sales of gastrin based therapies if any product is successfully commercialized.

Transition and Lilly will both participate in the currently planned phase II clinical trial with lead compound TT-223 in type 2 diabetes. Thereafter, Lilly will be responsible for further development activities and the commercialization of all gastrin based therapeutic products worldwide.

Exelixis says Genentech exercises option to develop cancer drug

March 14, 2008

Under the terms of the collaboration agreement between the parties, Exelixis will continue to be responsible for the phase 1 clinical trial until the point that a maximum tolerated dose (MTD) is determined. After MTD is achieved, Genentech will be responsible for completing the phase 1 clinical trial and subsequent clinical development.

Silence Therapeutics and AstraZeneca in collaboration to develop novel approaches for siRNA delivery

March 13, 2008

The deal builds on Silence Therapeutics' leading expertise in the delivery of siRNA molecules, in particular its success with the functional systemic delivery of siRNA in vivo using its proprietary AtuPLEX technology.

This new deal is independent of the parties' three-year collaboration signed in July 2007, whose aim is to develop novel siRNA therapeutics against specific targets exclusive to AstraZeneca.

M's Science and Eisai sign option agreement for sigma agonist SA4503

March 12, 2008

Under the terms of the agreement, M's Science will grant Eisai the following rights in exchange for a certain payment: the first review right for evaluating the results of the two Phase II studies of the compound currently ongoing in Europe for the above two indications and the first negotiation right regarding the development and marketing of the compound.

International Partnership for Microbicides receives license for novel HIV microbicide candidate from Merck

March 11, 2008

Under the terms of the agreement, Merck grants IPM full royalty-free rights to develop L'644 as a microbicide to prevent HIV infection in women in developing countries, while also collaborating with IPM to advance early stage product development research efforts.

Marcadia Biotech and Merck in diabetes and obesity collaboration

March 7, 2008

Under the terms of the agreement Merck will pay Marcadia an initial upfront fee as well as payments for exclusivity and ongoing collaborative research.

Marcadia will also be eligible to receive future milestone and royalty payments associated with research, development and commercialization of certain drug candidates.

Merck has obtained a worldwide exclusive license to certain Marcadia development candidates and intellectual property. Marcadia will also have the right to exercise options for profit and cost sharing and co-promotion in the United States.

Genta and Daiichi Sankyo in licensing deal for Tesetaxel

March 7, 2008

Under terms of the agreement, Daiichi Sankyo will receive upfront payments, payments pursuant to the achievement of certain milestones, and royalties on product sales.

Abbott, Genentech, Roche and OSI collaborate on molecular test for lung cancer therapy response

March 7, 2008

Under the agreement, Abbott will develop a test to detect extra copies of the epidermal growth factor receptor (EGFR) gene using its proprietary fluorescence in situ hybridization (FISH) technology in NSCLC. Financial terms of the agreement were not disclosed.

Amgen buys licensing rights from Kyowa Hakko for humanized monoclonal antibody KW-0761

March 6, 2008

Under the terms of the deal, Amgen will make an upfront payment to Kyowa Hakko of $100 million. Kyowa Hakko could receive up to $420 million in additional payments, including development, approval and sales milestones. Kyowa Hakko will also be entitled to receive double digit royalties on sales.

Endo buys rights to Novartis product

March 5, 2008

Licensing agreement with Novartis to obtain the exclusive U.S. marketing rights for the prescription medicine Voltaren gel.

Bayer HealthCare and Juvaris in licensing deal

March 4, 2008

Under the terms of the agreement, Bayer HealthCare will have complete access in the veterinary field to the Juvaris mono-immunotherapy and vaccine technology, which is being developed by Juvaris for human health care. The companies will evaluate and execute product development programs directed at immune stimulation and disease prevention in a variety of animal species.

In addition, the agreement anticipates that Bayer Animal Health will help financially support Juvaris' research, product formulation, development and GMP manufacturing activities to support its alliance obligations. The license is worldwide in scope. The financial terms of the deal have not been disclosed.

PsychoGenics and Dainippon Sumitomo sign drug discovery agreement

March 4, 2008

Drug discovery agreement to screen selected Dainippon Sumitomo Pharma compounds in PsychoGenics’ proprietary Drug Discovery Systems, with the aim of identifying new therapies for CNS disorders.

Pfizer to acquire Serenex to extend oncology pipeline

March 3, 2008

Pfizer will acquire the rights to SNX-5422, an oral Hsp90 inhibitor currently in Phase I trials for the potential treatment of solid tumors and hematological malignancies.

Pfizer will also acquire Serenex’s proprietary drug discovery technology and extensive small molecule Hsp90 inhibitor compound library.

Compounds from this library have potential uses in treating deadly and debilitating diseases, such as cancer, inflammatory and neurodegenerative diseases. SNX-1012, another compound in clinical development for the treatment of oral mucositis in cancer patients, is not included in the agreement.

Crucell in vaccine development agreement with Wyeth

March 3, 2008

Under the terms of the agreement, Crucell will be responsible for the development and manufacture of certain components of a vaccine for use by Wyeth in clinical studies. The development activities will take place in Crucell's dedicated vaccine manufacturing facilities in Bern, Switzerland. Wyeth will be responsible for the clinical development of the vaccine. Financial details were not disclosed.

MicroDose Technologies grants global license to Merck for MicroDose inhaler

March 3, 2008

Under the terms of the agreement, Merck will fund development and commercialization of products that employ MicroDose's DPI technology for the administration of Merck compounds. MicroDose will receive an upfront payment and will be eligible for milestone payments totaling $32 million for successful development of the first product as well as royalties on product revenues. Additional products will also be eligible for milestones and royalties.

BioWa expands of license agreement with Genentech

March 3, 2008

Under the terms of the expanded license agreement, BioWa will grant to Genentech commercial rights to research, develop, manufacture and commercialize antibodies utilizing POTELLIGENT Technology for an additional number of targets. In return, BioWa will receive milestone payments and royalties on products developed by Genentech. Additional terms were not disclosed.

OneWorld Health, Amyris Biotechnologies, and Sanofi-Aventis in development deal for semisynthetic artemisinin

March 3, 2008

This collaboration aims to create a complementary source of non-seasonal, high-quality and affordable artemisinin to supplement the current botanical supply, thereby enabling millions of people infected with malaria to gain consistent access to lower-cost, life-saving artemisinin-based combination therapies.

Under the terms of the agreement, OneWorld Health, Amyris and sanofi-aventis will work jointly to develop and design pilot and commercial scale manufacturing processes, with the goal of introducing low-cost, semisynthetic artemisinin into the supply chain and ACTs in 2010.

February 2008

Merck retains rights to certain AstraZeneca drugs

February 28, 2008

Merck has advised AstraZeneca PLC that it will not exercise its option to sell its interest in certain AstraZeneca non-proton pump inhibitor products this year. Those products are Atacand, Lexxel, Plendil and Entocort plus certain products currently in clinical development.

Receptor Logic and Sanofi Pasteur to develop T-cell receptor mimics for vaccine research

February 27, 2008

Under a collaborative research and exclusive license agreement, Receptor Logic will create custom TCRm in support of sanofi pasteur’s vaccine programs.

Abbott, Genentech and WEHI collaborate to research and develop new anti-cancer drugs

February 27, 2008

Under the terms of the collaboration the three parties are engaged in a drug discovery research program, with Genentech and Abbott being responsible for the development, manufacturing and commercialization of potential new drugs.

The discovery stage of the collaboration involves an integrated approach engaging research sites in South San Francisco, the Chicago area and Melbourne. Financial terms of the collaboration will not be disclosed.

Baxter Healthcare and Capsule form partnership

February 25, 2008

The collaboration allows Baxter to leverage Capsule’s DataCaptor Connectivity Suite with Baxter’s COLLEAGUE Volumetric infusion pumps. This agreement will provide Baxter with a wired and wireless connectivity solution that can connect the COLLEAGUE pump to many healthcare information systems.

Nycomed successfully completes acquisition of Bradley Pharmaceuticals

February 22, 2008

With this acquisition, Nycomed will expand the line of dermatological products currently offered through its PharmaDerm Division and thereby increase market coverage and drive future growth. Combined with Nycomed's Fougera Division, which is a leader in the topical prescription market in the US, total annualized sales will be $450 million, making Nycomed a leader in the dermatology market. Additionally, the combined specialty sales force now places Nycomed among the top five in sales forces selling prescription therapeutics in the US dermatology market.

Millipore signs license agreement with Bayer HealthCare

February 21, 2008

The license will enable Bayer to more efficiently manufacture recombinant proteins in mammalian cells by generating higher protein yields in its upstream bioprocessing operations. Financial terms were not disclosed.

Pfizer to acquire Encysive and Thelin lung drug

February 20, 2008

Under the terms of the agreement, Pfizer will make a cash tender offer for all issued and outstanding shares of Encysive for $2.35 per share, representing an equity value of approximately $195 million. Following completion of the tender offer, a subsidiary of Pfizer will merge with Encysive, with the outstanding Encysive shares not tendered pursuant to the tender offer converted into the right to receive the per share price paid under the offer.

Upon Pfizer's acquisition of Encysive, Pfizer will assume Encysive's change of control repurchase obligations under its 2.5% convertible senior notes. The Board of Directors of Encysive has unanimously approved the merger agreement and unanimously recommends that Encysive stockholders accept the tender offer and tender their shares.

Pfizer will acquire the rights to THELIN® (sitaxsentan sodium), an oral, once-daily endothelin A receptor antagonist (ETRA) for the treatment of PAH, as well as Encysive’s other pipeline candidates.

Antisense licenses ATL1102 to Teva

February 20, 2008

Under the terms of the agreement, ANP will receive an initial US$2 million up-front payment. ANP also has the potential to receive payments related to the continued clinical development of ATL1102 for MS upon certain future development milestones, with more significant milestone payments for entry into the market, and sales targets in particular territories.

The License includes potential milestone payments of up to US$100 million for the MS indication which is contingent upon completion of R&D, successful commercialization and meeting certain sales milestones, and bears inherent risks as does all pharmaceutical R&D. Teva would fund and perform all future development of ATL1102 beyond the current trial, should they decide to continue beyond that point.

If ANP fails to meet a particular development milestone regarding completion of the current ongoing, fully enrolled Phase IIa study by the agreed date in mid 2008, Teva may terminate the agreement and receive a US$2 million termination fee.

Royalties are payable on net sales of ATL1102 are in the low double digit range and are tiered according to annual net sales achieved. The agreement also provides an option for Teva to in-license ATL1102 as an aerosol drug for asthma.

Genstruct in new collaboration with Pfizer in drug safety

February 20, 2008

A master research agreement with Pfizer designed to cover current and future collaborations. The first collaboration under this new agreement is in the area of preclinical drug safety, focusing initially on a systems biology analysis of underlying mechanisms of drug-induced liver injury.

Pinnacle Biologics in marketing and distribution agreement with MedImmune

February 19, 2008

Exclusive distribution agreement with MedImmune for Ethyol (amifostine). The agreement, which is scheduled to take effect on June 1, 2008, grants Pinnacle Biologics exclusive Ethyol marketing authorization, certain licenses and distribution rights in Western Europe, Turkey and Israel. Additional terms of the agreement were not disclosed.

Biolex in deal with Merck KGaA for antibody optimization

February 19, 2008

The cooperation will evaluate the ability of the LEX System to improve therapeutic profiles through optimization of antibody glycosylation structures.

EUSA Pharma out-licenses preclinical-stage human antibody to GlaxoSmithKline

February 18, 2008

Out-licensed the exclusive world-wide rights to its preclinical-stage human anti-interleukin-6 antibody to GlaxoSmithKline for a consideration of up to $44 million, comprising an upfront fee and development milestones, plus royalties on future sales.

As part of the agreement EUSA will pay approximately 50% of the overall consideration to its development partner for the antibody, Vaccinex Inc. GSK will fund and conduct all future development, production and commercialization of the product.

Sanofi Pasteur and Statens Serum Institut team up against tuberculosis

February 14, 2008

Under the terms of the agreement, SSI has granted sanofi pasteur a license to its technology with regard to the use of certain fusion proteins in the development of a tuberculosis vaccine. The license from SSI includes access to the Intercell IC31(R) adjuvant. If the development is successful, sanofi pasteur would manufacture the vaccine commercially.

Vaccinex antibody licensed to GlaxoSmithKline

February 13, 2008

According to the terms of the product license, GSK will pay an up-front license fee, development milestones, and royalties on product sales to acquire the exclusive world-wide rights to develop and commercialize OP-R003 for the treatment of rheumatoid arthritis and other disease indications. Vaccinex will share 50% of fees, payments and royalties.

The antibody was discovered by Vaccinex utilizing its ActivMAb antibody discovery technology and first licensed for co-development by EUSA Pharma (formerly OPi SA).

Sanofi-Aventis and Dyax in deal on DX-2240 antibody

February 12, 2008

Under the terms of the two agreements, Dyax is eligible to receive up to $500 million in license fees and milestone payments in the case of full commercial success of the first five antibody candidates, including DX-2240. Dyax will receive $25 million in 2008. In addition, Dyax is eligible to receive royalties based on commercial sales of DX-2240 and other antibodies developed by sanofi-aventis.

As exclusive licensee, sanofi-aventis will be responsible for the ongoing development, commercialization and consolidation of sales of DX-2240. For certain other future antibody product candidates discovered by sanofi-aventis, Dyax will retain co-development and profit sharing rights, while sanofi-aventis will maintain the leadership in development and commercialization, and book sales worldwide.

Meditrina Pharma in global license agreement with AstraZeneca

February 6, 2008

Agreement to make, develop and commercialize products under AstraZeneca's IP and know-how regarding the use of aromatase inhibitors (AI) in combination with estrogen and progestin to treat endometriosis.

This agreement expands Meditrina's clinical stage product portfolio which currently includes Femathina(MPI- 674), an AI that Meditrina is repurposing for the treatment of several serious women's health conditions, including endometrial thinning prior to endometrial ablations in premenopausal women with abnormal uterine bleeding (AUB). Femathina recently completed a phase II clinical trial.

Amgen and Takeda Pharmaceutical in exclusive tie-up for Japanese market

February 4, 2008

Takeda will develop and commercialize for the Japanese market up to 13 molecules from Amgen’s pipeline, one of which is included as an option. This collaboration validates the significant value of Amgen’s clinical stage pipeline and further ensures Japanese patients will have access to Amgen’s innovative potential medicines for serious illnesses. The collaboration includes early to mid-stage clinical-stage candidates across a range of therapeutic areas, including oncology, inflammation, and pain.

The financial terms include an upfront cash payment to Amgen of $200 million. Takeda will also pay to Amgen up to $340 million in expected worldwide development costs for these molecules over the next several years, $362 million in success-based milestone payments, and double digit royalties on sales in Japan. Additionally, Takeda plans to acquire all the shares of Amgen’s Japanese subsidiary, Amgen KK. We anticipate the share transaction to close in the first quarter.

In addition, Takeda will become Amgen’s worldwide partner for motesanib diphosphate (AMG 706), and will pay Amgen $100 million upfront, $175 million in success-based milestones for the first two indications, and double digit royalties on sales in Japan. Takeda will also pay 60 percent of ongoing clinical development expenses outside Japan and share potential profits outside Japan 50/50.

GlaxoSmithKline and Amira in FLAP (5-Lipoxygenase Activating Protein ) inhibitors deal

February 4, 2008

Under the terms of the agreement GSK will be granted an exclusive, worldwide license to develop, manufacture and commercialize Amira's FLAP inhibitors, including AM103 and other compounds within the current development program. In the event that all potential development and regulatory milestones are successfully achieved, Amira could receive up to US $425 million in upfront and milestone payments.

In addition, Amira will be entitled to receive tiered royalty payments based on worldwide net sales and commercial sales milestones.

Merck KGaA signs licensing agreement with Sol-Gel

February 4, 2008

This licensing agreement allows Merck, besides the exclusive rights to marketing and global sales, also the permission to manufacture Sol-Gel's UV-Pearls. Behind the UV-Pearls brand name hides a technology developed by Sol-Gel Technologies to encapsulate UV absorbers.

Paladin Labs and Nycomed enter Canadian co-promotion deal for Tridural once-daily Tramadol product

February 1, 2008

Under this co-promotion agreement, Nycomed Canada will share brand responsibilities and expenses with Paladin and will deploy a national primary care sales force to promote Tridural.

Paladin will continue to handle distribution of Tridural and will also continue to promote Tridural using its primary care sales force.

January 2008

Iroko Pharmaceuticals acquires rights to cardiovascular product from Merck & Co

January 31, 2008

Acquisition of all non-US commercial rights to Aggrastat (tirofiban HCl) from Merck & Co., Inc.

PsychoGenics expands discovery relationship with Eli Lilly

January 31, 2008

PsychoGenics and Lilly aim to jointly identify drug candidates suitable for clinical development. Upon Lilly's further development of clinical candidates, PsychoGenics would receive research and milestone payments, and royalties.

International Partnership for Microbicidesand Pfizer to develop antiretroviral drug as vaginal microbicide

January 30, 2008

This agreement marks only the second time a pharmaceutical company has licensed an already approved HIV therapy to be developed as a microbicide. Researchers hope that maraviroc's safety and efficacy data as a therapeutic will speed its development as a microbicide.

Under this agreement, IPM would work to develop maraviroc as a vaginal microbicide with the right to develop, manufacture and distribute the microbicide in developing countries. Pfizer has granted these rights to IPM without a royalty.

Sepracor acquires US rights to Nycomed's Alvesco HFA and Omnaris AQ plus ciclesonide pipeline

January 29, 2008

Nycomed will receive an upfront payment of $150 million and may become entitled to receive subsequent payments of up to $280 million over the life of the agreement upon accomplishment of various development and sales milestones. Nycomed will also receive compensation for providing finished product, and royalties on sales of ciclesonide products.

TransTech acquires three programs for the treatment of metabolic disorder from Novo Nordisk

January 25, 2008

The portfolio is comprised of three distinct therapeutic approaches to such treatment: H3 receptor antagonists, PPARd agonists, and 11BHSD1 inhibitors.

BioMS Medical completes multiple sclerosis licensing deal with Lilly

January 25, 2008

As part of the agreement, BioMS has received an upfront cash payment of US$87 million. In December, 2007 BioMS Medical entered into a global licensing and development agreement granting Lilly exclusive worldwide rights to BioMS Medical's lead drug, MBP8298, for the treatment of multiple sclerosis.

MD Anderson Cancer Center and AstraZeneca in alliance to advance understanding of cancer

January 24, 2008

The new alliance will focus on identifying neurobiological differences between cancer patients who develop chemotherapy-induced pain and patients who experience little or no pain.

Scientists at M. D. Anderson and AstraZeneca hope to better understand the mechanisms through which chemotherapies cause peripheral nerve dysfunctions, such as numbness and tingling, and severe pain. Research could lead to new treatments to prevent pain -- extending the therapeutic value of current chemotherapies -- as well as help in the development of new chemotherapies with less severe pain-related side effects.

BioSeek initiates drug discovery collaboration with Dainippon Sumitomo

January 24, 2008

Under the collaboration, BioSeek will apply its BioMAP(R) Systems to support compound differentiation, lead development, and drug candidate selection activities for DSP's discovery programs in the fields of inflammation and metabolic diseases.

Paul Capital Healthcare purchases additional royalty interest in GSK's Rotarix fund's third investment in vaccine to prevent rotavirus

January 23, 2008

Under the terms of this agreement, Paul Capital Healthcare acquired all royalties on worldwide sales of Rotarix from Cincinnati Children's. This is the third investment that the Fund has completed related to Rotarix royalties.

In November 2005, Paul Capital Healthcare acquired an interest in Rotarix from three inventors at Cincinnati Children's; and in May 2005 acquired a portion of AVANT Immunotherapeutics' total royalties on Rotarix.

Teva to acquire CoGenesys for $400 million

January 22, 2008

Under terms of the agreement, Teva will pay a purchase price of $400 million cash, funded from its internal resources. The transaction has been approved by the boards of directors of each company and by the shareholders of CoGenesys and is subject to customary closing conditions (including approval under the Hart-Scott-Rodino Antitrust Improvements Act of 1976), and is expected to close during the first half of 2008.

Exelixis and Bristol-Myers Squibb to co-develop XL139

January 22, 2008

Under the terms of the collaboration agreement between the two companies, which became effective in January 2007, the selection of XL139 by Bristol-Myers Squibb entitles Exelixis to a milestone payment of $20 million.

In addition, Exelixis has exercised its option under the collaboration agreement to co-develop and co-commercialize XL139 in the United States. Following the transfer of the XL139 development program, which is expected to occur promptly, Bristol-Myers Squibb will lead all global activities. The parties will co-develop and co-commercialize XL139 in the U.S. and share those profits 50/50. Exelixis will be entitled to receive double-digit royalties on product sales outside of the U.S.

Novexel and Forest in license agreement for NXL 104

January 22, 2008

Under the terms of the agreement, Forest will pay Novexel an upfront license payment of euro 75 million. Forest will fund development and commercialization of the ceftaroline/NXL 104 combination.

Additional milestone payments to Novexel if the combination product is successfully developed could total euro 75 million. Following the product's regulatory marketing approval, Forest will pay Novexel a low double digit royalty on product sales throughout North America.

Aureon collaborate with Pfizer to establish quantitative biometrics for assessing therapeutic response of prostate cancer patients using hormone therapy

January 22, 2008

The collaboration is an extension of a previous study performed by Aureon and Pfizer to evaluate prostatectomy samples from patients treated with neo-adjuvant androgen deprivation therapy (ADT). The previous project also demonstrated the technical feasibility of Aureon’s platform in quantifying T-cell subtypes in a lymphoid infiltrate and the cellular distribution of cytokines using intact formalin-fixed, paraffin-embedded (FFPE) tissue specimens.

Roche extends offer to acquire Ventana Medical Systems

January 17, 2008

Roche extended its offer to acquire all of the outstanding common shares of Ventana Medical Systems to March 14, 2008.

Teva Specialty Pharmaceuticals and UCB in US respiratory collaboration

January 16, 2008

The initial product to be jointly promoted in the U.S. is Teva’s ProAir HFA (albuterol sulfate) Inhalation Aerosol. Additionally, the agreement will provide UCB future joint promotion opportunities with other products in development by Teva Specialty Pharmaceuticals. Financial terms of the agreement were not disclosed.

Pfizer in $250M tissue regeneration deal

January 16, 2008

Under this agreement, Pfizer will obtain a worldwide exclusive license to develop and commercialize CD-RAP. In addition to receiving royalties on the sale of any products that may be commercialised under this agreement, Scil is eligible for upfront and milestone payments of approximately U.S. $250 million depending on the achievement of various development and regulatory milestones.

Millennium Biotechnologies in product development agreement

January 16, 2008

A one year Product Development Agreement with Provider Services, Inc. of Cleveland, Ohio.

Genzyme in license agreement with Moffitt Cancer Center for lung cancer diagnostic

January 15, 2008

Under the license agreement, Genzyme has agreed to pay Moffitt when various milestones are reached and provide Moffitt with running royalties on the sales of licensed services and products.

ImmunoVaccine licenses VacciMax to Pfizer Animal Health

January 14, 2008

The terms of the agreements were not disclosed, IVT will receive upfront signing fees, milestone and royalty payments.

Compugen in GPCR ligand discovery and license option agreement with Merck

January 14, 2008

The agreement includes an option to Merck for exclusive worldwide licenses for such peptides – on a peptide by peptide basis – covering the development and commercialization of therapeutic products.

Celltrion and CSL in collaboration to develop and manufacture monoclonal antibody

January 10, 2008

As part of the collaboration, Celltrion will provide process development expertise and supply clinical and commercial material to support the clinical development program for CSL 360 and commercialization of the product, with the potential for a longer term strategic manufacturing relationship between the companies in the future.

Antitope in EpiScreen collaboration with UCB Celltech

January 9, 2008

Antitope will apply EpiScreen technology to profile the immunogenicity of therapeutic monoclonal antibodies.

Biogen Idec and PDL BioPharma license rights to develop volociximab in ophthalmic indications to Ophthotech

January 8, 2008

Under the terms of the agreement, Biogen Idec and PDL have granted Ophthotech worldwide development and commercial rights to all ophthalmic uses of volociximab (M200). Volociximab is an investigational monoclonal antibody targeting α5β1 integrin, a key protein involved in the formation of blood vessels, a process known as angiogenesis.

Biogen Idec and PDL will each receive an equity position in Ophthotech as well as a combination of development milestone payments and royalties on future product sales. Other terms, including financial terms, related to the agreement have not been disclosed.

Genzyme and Isis in alliance to develop and commercialize mipomersen

January 7, 2008

Genzyme will pay Isis $150 million to purchase five million shares of Isis common stock for $30 per share upon Hart-Scott-Rodino clearance. Upon completion of final contracts, Genzyme will pay Isis a $175 million up-front mipomersen license fee. In addition to this initial $325 million, Isis has the potential to receive significant milestone payments for mipomersen, which is currently in phase 3 trials. Once the product is launched, the two companies will share profits.

Tacere Therapeutics enters collaboration with Pfizer to develop and commercialize RNAi hepatitis C drug

January 7, 2008

Under the terms of the agreement, Tacere and Pfizer will form a joint steering committee to oversee preclinical research and development efforts for TT-033. Pfizer will fund all aspects of the collaboration, including the preclinical development work and will have exclusive worldwide rights, excluding all Asian countries, to commercialize products that result from the collaboration.

During the initial phase of the collaboration, Pfizer will provide Tacere with funding in order to complete the necessary IND-enabling studies for TT-033. In addition, Tacere will be eligible to receive milestone payments through successful achievement of development, approval, and commercialization milestones resulting in total potential payments to Tacere of over $145 million. Upon commercialization of TT-033 Tacere would be entitled to receive royalties on net sales by Pfizer.

Magen licenses dermatology assets from Eli Lilly

January 7, 2008

Under the terms of the agreement, Magen has been granted the exclusive worldwide rights to develop and commercialize products based on these compounds for all dermatology applications.

Pfizer and Taisho in deal for schizophrenia drug

January 7, 2008

Taisho will grant exclusive development and commercialization rights outside Japan for TS-032 to Pfizer. Under the agreement, Taisho will receive from Pfizer an initial payment of U.S. $22 million. Taisho will also receive milestone payments tied to progress of development, as well as royalties and milestone payments tied to sales if TS-032 is approved by regulatory authorities and launched.

Genomic Health in collaboration with Pfizer to develop prognostic test for non-metastatic renal cell carcinoma

January 7, 2007

As part of the collaboration, the companies will apply the same molecular technology and clinical strategy Genomic Health used to develop its Oncotype DX breast cancer test.

Faust Pharmaceuticals in research agreement with Takeda

January 7, 2008

Faust's NEUROCLID GPCR platform will be used to identify drug candidates for specific GPCR targets. Financial terms of the research agreement were not disclosed.

Galapagos in oncology collaboration with Janssen

January 3, 2008

The goal of the new collaboration will be to discover and validate novel targets in the field of oncology. BioFocus DPI will perform assay development, screening of the SilenceSelect and FLeXSelect adenoviral libraries, and target validation. Target discovery in cutting edge in vitro assays may provide novel drug targets for cancer areas with an unmet medical need.

BioFocus DPI receives an upfront payment of EUR 2.9 million. In total, BioFocus DPI may receive additional research, acceptance, license and development fees of up to EUR 7.6 million should certain predetermined criteria be achieved.

Crucell in rabies antibodies deal with Sanofi-Aventis

January 3, 2008

Under the terms of the agreement, Crucell will continue to perform the development activities. Crucell will be responsible for the manufacturing of the final product and will retain exclusive distribution rights in Europe, co-exclusive distribution rights in China and the rights to sell to supranational organizations such as UNICEF. Crucell will receive a payment of EUR 10 million following the execution of the agreement, will be eligible for milestone payments of up to EUR 66.5 million and will receive an undisclosed percentage on sales of the final product by sanofi pasteur.

Akela licenses Fentanyl TAIFUN to Janssen for Canada

January 3, 2008

The existing agreement with Janssen Pharmaceutica NV already covers the European Union, Eastern Europe, Russia, the Middle-East and Africa. All the commercial and contractual conditions remain in effect. The product will be distributed by Janssen-Ortho Inc for the Canadian market. Akela Pharma will receive a signing fee, development and regulatory milestones as well as commercial sales milestones that are in line with current commercial expectations regarding the Canadian market as compared with the European Union market.

Merck and Addex in $700M schizophrenia deal

January 3, 2008

Under the terms of the agreement, Addex will receive $22 million upfront and is eligible for up to $455 million in research, development, regulatory and sales milestones for the first product developed for two indications and up to $225 million in additional development, regulatory and sales milestones for a second product developed in two indications. Addex is eligible to receive royalties on sales of any products resulting from this collaboration. In addition, Addex has an option to co-promote in certain European Union countries and will participate in the joint oversight committee for further development that will be led by Merck.